# EDGAR Filing Document

**Accession Number:** 0001729149
**File Stem:** 0001729149-25-000119
**Filing Date:** 2025-8
**Character Count:** 169202
**Document Hash:** 3d93cf264e34e01fd13d61cea86171ee
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001729149-25-000119.hdr.sgml**: 20250806

**ACCESSION NUMBER**: 0001729149-25-000119

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 69

**CONFORMED PERIOD OF REPORT**: 20250630

**FILED AS OF DATE**: 20250806

**DATE AS OF CHANGE**: 20250806

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** VIEMED HEALTHCARE, INC.
- **CENTRAL INDEX KEY:** 0001729149
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 000000000
- **STATE OF INCORPORATION:** A1
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38973
- **FILM NUMBER:** 251190596

**BUSINESS ADDRESS:**
- **STREET 1:** 625 E. KALISTE SALOOM RD.
- **CITY:** LAFAYETTE
- **STATE:** LA
- **ZIP:** 70508
- **BUSINESS PHONE:** 337.504.3802

**MAIL ADDRESS:**
- **STREET 1:** 625 E. KALISTE SALOOM RD.
- **CITY:** LAFAYETTE
- **STATE:** LA
- **ZIP:** 70508

?xml version='1.0' encoding='ASCII'? vmd-20250630

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**Form 10-Q**

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2025

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to _____

Commission file number: 001-38973

**Viemed Healthcare, Inc.**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **British Columbia, Canada** | | **N/A** |
| (State or other jurisdiction of<br>incorporation or organization) |  | (IRS Employer<br>Identification Number) |
|  | **625 E. Kaliste Saloom Rd.**<br>**Lafayette, LA 70508** |  |
| (Address of principal executive offices, including zip code) | (Address of principal executive offices, including zip code) | (Address of principal executive offices, including zip code) |
|  | **(337) 504-3802** |  |
| (Registrant's telephone number, including area code) | (Registrant's telephone number, including area code) | (Registrant's telephone number, including area code) |

---

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of exchange on which registered** |
| Common Shares, no par value | VMD | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ⌧&nbsp;&nbsp;&nbsp;&nbsp;No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&nbsp;&nbsp;&nbsp;&nbsp;Yes ⌧&nbsp;&nbsp;&nbsp;&nbsp;No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐ Accelerated filer ☒ Non-Accelerated filer ☐ Smaller reporting company ☐Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&nbsp;&nbsp;&nbsp;&nbsp;Yes ☐&nbsp;&nbsp;&nbsp;&nbsp;No ⌧

As of July 31, 2025, there were 38,785,759 common shares of the registrant outstanding.

------

---

| |
|:---|
| **VIEMED HEALTHCARE, INC.**<br>**TABLE OF CONTENTS** |
| **June 30, 2025 and 2024** |

---

---

| | |
|:---|:---|
| | Page |
| <u>[PART I - FINANCIAL INFORMATION](#i4d2365a9707840b5be7eda4fe740ce44_16)</u> | <u>[3](#i4d2365a9707840b5be7eda4fe740ce44_16)</u> |
| <u>[Item 1. Financial Statements](#i4d2365a9707840b5be7eda4fe740ce44_16)</u> | <u>[3](#i4d2365a9707840b5be7eda4fe740ce44_16)</u> |
| <u>[Condensed Consolidated Balance Sheets](#i4d2365a9707840b5be7eda4fe740ce44_16)</u> | <u>[3](#i4d2365a9707840b5be7eda4fe740ce44_16)</u> |
| <u>[Condensed Consolidated Statements of Income](#i4d2365a9707840b5be7eda4fe740ce44_22)</u> | <u>[4](#i4d2365a9707840b5be7eda4fe740ce44_22)</u> |
| <u>[Condensed Consolidated Statements of Changes in Shareholders' Equity](#i4d2365a9707840b5be7eda4fe740ce44_25)</u> | <u>[5](#i4d2365a9707840b5be7eda4fe740ce44_25)</u> |
| <u>[Condensed Consolidated Statements of Cash Flows](#i4d2365a9707840b5be7eda4fe740ce44_28)</u> | <u>[6](#i4d2365a9707840b5be7eda4fe740ce44_28)</u> |
| <u>[Notes to the Condensed Consolidated Financial Statements](#i4d2365a9707840b5be7eda4fe740ce44_31)</u> | <u>[7](#i4d2365a9707840b5be7eda4fe740ce44_31)</u> |
| <u>[Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](#i4d2365a9707840b5be7eda4fe740ce44_88)</u> | <u>[22](#i4d2365a9707840b5be7eda4fe740ce44_88)</u> |
| <u>[Forward-Looking Statements](#i4d2365a9707840b5be7eda4fe740ce44_91)</u> | <u>[22](#i4d2365a9707840b5be7eda4fe740ce44_91)</u> |
| <u>[General Matters](#i4d2365a9707840b5be7eda4fe740ce44_94)</u> | <u>[23](#i4d2365a9707840b5be7eda4fe740ce44_94)</u> |
| <u>[Overview](#i4d2365a9707840b5be7eda4fe740ce44_97)</u> | <u>[23](#i4d2365a9707840b5be7eda4fe740ce44_97)</u> |
| <u>[Trends Affecting Our Business](#i4d2365a9707840b5be7eda4fe740ce44_100)</u> | <u>[24](#i4d2365a9707840b5be7eda4fe740ce44_100)</u> |
| <u>[Results of Operations](#i4d2365a9707840b5be7eda4fe740ce44_103)</u> | <u>[27](#i4d2365a9707840b5be7eda4fe740ce44_103)</u> |
| <u>[Non-GAAP Financial Measures](#i4d2365a9707840b5be7eda4fe740ce44_106)</u> | <u>[33](#i4d2365a9707840b5be7eda4fe740ce44_106)</u> |
| <u>[Liquidity and Capital Resources](#i4d2365a9707840b5be7eda4fe740ce44_109)</u> | <u>[34](#i4d2365a9707840b5be7eda4fe740ce44_109)</u> |
| <u>[Accounting and Disclosure Matters](#i4d2365a9707840b5be7eda4fe740ce44_112)</u> | <u>[37](#i4d2365a9707840b5be7eda4fe740ce44_112)</u> |
| <u>[Item 3. Quantitative and Qualitative Disclosures About Market Risk](#i4d2365a9707840b5be7eda4fe740ce44_115)</u> | <u>[38](#i4d2365a9707840b5be7eda4fe740ce44_115)</u> |
| <u>[Item 4. Controls and Procedures](#i4d2365a9707840b5be7eda4fe740ce44_118)</u> | <u>[38](#i4d2365a9707840b5be7eda4fe740ce44_118)</u> |
| <u>[PART II - OTHER INFORMATION](#i4d2365a9707840b5be7eda4fe740ce44_121)</u> | <u>[39](#i4d2365a9707840b5be7eda4fe740ce44_121)</u> |
| <u>[Item 1. Legal Proceedings](#i4d2365a9707840b5be7eda4fe740ce44_124)</u> | <u>[39](#i4d2365a9707840b5be7eda4fe740ce44_124)</u> |
| <u>[Item 1A. Risk Factors](#i4d2365a9707840b5be7eda4fe740ce44_127)</u> | <u>[39](#i4d2365a9707840b5be7eda4fe740ce44_127)</u> |
| <u>[Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](#i4d2365a9707840b5be7eda4fe740ce44_130)</u> | <u>[41](#i4d2365a9707840b5be7eda4fe740ce44_136)</u> |
| <u>[Item 3. Defaults Upon Senior Securities](#i4d2365a9707840b5be7eda4fe740ce44_133)</u> | <u>[41](#i4d2365a9707840b5be7eda4fe740ce44_133)</u> |
| <u>[Item 4. Mine Safety Disclosures](#i4d2365a9707840b5be7eda4fe740ce44_136)</u> | <u>[41](#i4d2365a9707840b5be7eda4fe740ce44_136)</u> |
| <u>[Item 5. Other Information](#i4d2365a9707840b5be7eda4fe740ce44_139)</u> | <u>[41](#i4d2365a9707840b5be7eda4fe740ce44_139)</u> |
| <u>[Item 6. Exhibits](#i4d2365a9707840b5be7eda4fe740ce44_142)</u> | <u>[42](#i4d2365a9707840b5be7eda4fe740ce44_142)</u> |
| <u>[Signatures](#i4d2365a9707840b5be7eda4fe740ce44_145)</u> | <u>[43](#i4d2365a9707840b5be7eda4fe740ce44_145)</u> |

---

------

**PART I - FINANCIAL INFORMATION**

**Item 1. Financial Statements**

---

| | | | |
|:---|:---|:---|:---|
| **VIEMED HEALTHCARE, INC.<br>CONDENSED CONSOLIDATED BALANCE SHEETS** | **VIEMED HEALTHCARE, INC.<br>CONDENSED CONSOLIDATED BALANCE SHEETS** | **VIEMED HEALTHCARE, INC.<br>CONDENSED CONSOLIDATED BALANCE SHEETS** | **VIEMED HEALTHCARE, INC.<br>CONDENSED CONSOLIDATED BALANCE SHEETS** |
| ***(Expressed in thousands of U.S. Dollars, except outstanding shares)*** | ***(Expressed in thousands of U.S. Dollars, except outstanding shares)*** | ***(Expressed in thousands of U.S. Dollars, except outstanding shares)*** | ***(Expressed in thousands of U.S. Dollars, except outstanding shares)*** |
| | **Note** | **At<br>June 30, 2025** | **At<br>December 31, 2024** |
|  |  | *(Unaudited)* | *(Audited)* |
| **ASSETS** |  |  |  |
| **Current assets** |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash and cash equivalents | 2 | $20016 | $17540 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable, net | 2 | 26549 | 24911 |
| &nbsp;&nbsp;&nbsp;&nbsp;Inventory | 2 | 4324 | 4320 |
| &nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other assets |  | 4402 | 6109 |
| **Total current assets** |  | $55291 | $52880 |
| **Long-term assets** |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Property and equipment, net | 4 | 79735 | 76279 |
| &nbsp;&nbsp;&nbsp;&nbsp;Finance lease right-of-use assets |  | 13 | 50 |
| &nbsp;&nbsp;&nbsp;&nbsp;Operating lease right-of-use assets |  | 2639 | 2831 |
| &nbsp;&nbsp;&nbsp;&nbsp;Equity investments | 2 | 2794 | 2794 |
| &nbsp;&nbsp;&nbsp;&nbsp;Deferred tax asset | 10 | 10359 | 8398 |
| &nbsp;&nbsp;&nbsp;&nbsp;Identifiable intangibles, net |  | 783 | 848 |
| &nbsp;&nbsp;&nbsp;&nbsp;Goodwill | 3 | 32989 | 32989 |
| **Total long-term assets** |  | $129312 | $124189 |
| **TOTAL ASSETS** |  | $184603 | $177069 |
| **LIABILITIES** |  |  |  |
| **Current liabilities** |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Trade payables |  | $8253 | $5322 |
| &nbsp;&nbsp;&nbsp;&nbsp;Deferred revenue |  | 7193 | 6694 |
| &nbsp;&nbsp;&nbsp;&nbsp;Income taxes payable |  | 1450 | 3883 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accrued liabilities | 5 | 18644 | 20157 |
| &nbsp;&nbsp;&nbsp;&nbsp;Finance lease liabilities, current portion |  | 15 | 50 |
| &nbsp;&nbsp;&nbsp;&nbsp;Operating lease liabilities, current portion | 6 | 895 | 811 |
| &nbsp;&nbsp;&nbsp;&nbsp;Current portion of long-term debt | 6 | 820 | 409 |
| **Total current liabilities** |  | $37270 | $37326 |
| **Long-term liabilities** |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Accrued liabilities | 8 | 549 | 846 |
| &nbsp;&nbsp;&nbsp;&nbsp;Operating lease liabilities, less current portion | 6 | 1695 | 2007 |
| &nbsp;&nbsp;&nbsp;&nbsp;Long-term debt | 6 | 3465 | 3589 |
| **Total long-term liabilities** |  | $5709 | $6442 |
| **TOTAL LIABILITIES** |  | $42979 | $43768 |
| **Commitments and Contingencies** |  |  |  |
| **SHAREHOLDERS' EQUITY** |  |  |  |
| Common stock - No par value: unlimited authorized; 39,605,005 and 39,132,897 issued and outstanding as of June 30, 2025 and December 31, 2024, respectively | 8 | $27787 | $23365 |
| &nbsp;&nbsp;&nbsp;&nbsp;Additional paid-in capital |  | 18102 | 18337 |
| &nbsp;&nbsp;&nbsp;&nbsp;Retained earnings |  | 93842 | 89691 |
| **TOTAL VIEMED HEALTHCARE, INC.'S SHAREHOLDERS' EQUITY** |  | $139731 | $131393 |
| &nbsp;&nbsp;&nbsp;&nbsp;Noncontrolling interest in subsidiary | 3 | 1893 | 1908 |
| **TOTAL SHAREHOLDERS' EQUITY**  |  | 141624 | 133301 |
| **TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY** |  | $184603 | $177069 |

---

See accompanying notes to the condensed consolidated financial statements <br> Page 3

------

---

| |
|:---|
| **VIEMED HEALTHCARE, INC.**<br>**CONDENSED CONSOLIDATED STATEMENTS OF INCOME** |
| ***(Expressed in thousands of U.S. Dollars, except share and per share amounts)***<br>***(Unaudited)*** |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | | **Three Months Ended June 30,** | **Three Months Ended June 30,** | **Six Months Ended June 30,** | **Six Months Ended June 30,** |
| |<br>**Note** | **2025** | **2024** | **2025** | **2024** |
| **Revenue** | 2 | $63056 | $54965 | $122185 | $105558 |
| Cost of revenue |  | 26325 | 22073 | 52175 | 42864 |
| **Gross profit** |  | $36731 | $32892 | $70010 | $62694 |
| **Operating expenses** |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Selling, general and administrative |  | 28803 | 26503 | 57228 | 51317 |
| &nbsp;&nbsp;&nbsp;&nbsp;Research and development |  | 847 | 758 | 1644 | 1508 |
| &nbsp;&nbsp;&nbsp;&nbsp;Stock-based compensation | 8 | 2341 | 1620 | 4652 | 3052 |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization |  | 353 | 377 | 701 | 792 |
| &nbsp;&nbsp;&nbsp;&nbsp;Gain on disposal of property and equipment |  | (636) | (545) | (3004) | (332) |
| &nbsp;&nbsp;&nbsp;&nbsp; Other expense (income), net |  | (72) | 563 | (147) | 537 |
| **Income from operations** |  | $5095 | $3616 | $8936 | $5820 |
| **Non-operating income and expenses** |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Loss on investments |  |  | (1117) |  | (1050) |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest expense, net | 6 | (132) | (254) | (311) | (404) |
| **Net income before taxes** |  | 4963 | 2245 | 8625 | 4366 |
| &nbsp;&nbsp;&nbsp;&nbsp;Provision for income taxes | 10 | 1713 | 768 | 2665 | 1286 |
| **Net income** |  | $3250 | $1477 | $5960 | $3080 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net income attributable to noncontrolling interest |  | 93 | 9 | 178 | 9 |
| **Net income attributable to Viemed Healthcare, Inc.** |  | $3157 | $1468 | $5782 | $3071 |
| **Net income per share** |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Basic | 11 | $0.08 | $0.04 | $0.15 | $0.08 |
| &nbsp;&nbsp;&nbsp;&nbsp;Diluted | 11 | $0.08 | $0.04 | $0.14 | $0.08 |
| **Weighted average number of common shares outstanding:** |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Basic | 11 | 39515247 | 38822980 | 39471244 | 38558479 |
| &nbsp;&nbsp;&nbsp;&nbsp;Diluted | 11 | 41083760 | 40553449 | 41393523 | 40313042 |

---

See accompanying notes to the condensed consolidated financial statements <br> Page 4

------

---

| |
|:---|
| **VIEMED HEALTHCARE, INC.**<br>**CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY** |
| ***(Expressed in thousands of U.S. Dollars, except share and per share amounts)<br>(Unaudited)*** |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Common Stock** | **Common Stock** | **Additional paid-in capital** | | **Noncontrolling interest in subsidiary** | **Total Shareholders'<br>equity** |
| | **Shares** | **Amount** | **Additional paid-in capital** |<br>**Retained <br>earnings** | **Noncontrolling interest in subsidiary** | **Total Shareholders'<br>equity** |
| **Shareholders' equity, December 31, 2023** | **38506161** | $**18702** | $**15698** | $**79495** | $**—** | $**113895** |
| Stock-based compensation - options |  |  | 111 |  |  | 111 |
| Stock-based compensation - restricted stock  |  |  | 1321 |  |  | 1321 |
| Exercise of options | 60130 | 304 |  |  |  | 304 |
| Shares issued for vesting of restricted stock units | 378837 | 2836 | (2836) |  |  |  |
| Shares redeemed to pay income tax | (128362) |  |  | (961) |  | (961) |
| Net income |  |  |  | 1603 |  | 1603 |
| **Shareholders' equity, March 31, 2024** | **38816766** | $**21842** | $**14294** | $**80137** | $**—** | $**116273** |
| Stock-based compensation - options |  |  | 59 |  |  | 59 |
| Stock-based compensation - restricted stock  |  |  | 1561 |  |  | 1561 |
| Exercise of options | 4000 | 21 |  |  |  | 21 |
| Shares issued for vesting of restricted stock units | 6654 | 47 | (47) |  |  |  |
| Shares redeemed to pay income tax | (1621) |  |  | (11) |  | (11) |
| Acquired noncontrolling interest |  |  |  |  | 1800 | 1800 |
| Net income |  |  |  | 1468 | 9 | 1477 |
| **Shareholders' equity, June 30, 2024** | **38825799** | $**21910** | $**15867** | $**81594** | $**1809** | $**121180** |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Common Stock** | **Common Stock** | **Additional paid-in capital** | | **Noncontrolling interest in subsidiary** | **Total Shareholders'<br>equity** |
| | **Shares** | **Amount** | **Additional paid-in capital** |<br>**Retained <br>earnings** | **Noncontrolling interest in subsidiary** | **Total Shareholders'<br>equity** |
| **Shareholders' equity, December 31, 2024** | **39132897** | $**23365** | $**18337** | $**89691** | $**1908** | $**133301** |
| Stock-based compensation - options |  |  | 16 |  |  | 16 |
| Stock-based compensation - restricted stock  |  |  | 2295 |  |  | 2295 |
| Exercise of options | 2225 | 11 |  |  |  | 11 |
| Shares issued for vesting of restricted stock units | 581838 | 4775 | (4775) |  |  |  |
| Shares redeemed to pay income tax | (193173) |  |  | (1584) |  | (1584) |
| Net income |  |  |  | 2625 | 85 | 2710 |
| **Shareholders' equity, March 31, 2025** | **39523787** | $**28151** | $**15873** | $**90732** | $**1993** | $**136749** |
| Stock-based compensation - options |  |  | 6 |  |  | 6 |
| Stock-based compensation - restricted stock  |  |  | 2335 |  |  | 2335 |
| Exercise of options | 336633 | 1357 |  |  |  | 1357 |
| Shares issued for vesting of restricted stock units | 21293 | 145 | (145) |  |  |  |
| Shares redeemed to pay income tax | (6647) |  |  | (47) |  | (47) |
| Distribution to non-controlling interest |  |  |  |  | (193) | (193) |
| Shares repurchased under the share repurchase program | (270061) | (1866) | 33 |  |  | (1833) |
| Net income |  |  |  | 3157 | 93 | 3250 |
| **Shareholders' equity, June 30, 2025** | **39605005** | $**27787** | $**18102** | $**93842** | $**1893** | $**141624** |

---

See accompanying notes to the condensed consolidated financial statements <br> Page 5

------

---

| |
|:---|
| **VIEMED HEALTHCARE, INC.<br>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS** |
| ***(Expressed in thousands of U.S. Dollars)***<br>***(Unaudited)*** |

---

---

| | | | |
|:---|:---|:---|:---|
| | | **Six Months Ended June 30,** | **Six Months Ended June 30,** |
| |<br>**Note** | **2025** | **2024** |
| **Cash flows from operating activities** |  |  |  |
| Net income |  | $5960 | $3080 |
| Adjustments for: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization |  | 13504 | 12594 |
| &nbsp;&nbsp;&nbsp;&nbsp;Stock-based compensation expense | 8 | 4652 | 3052 |
| &nbsp;&nbsp;&nbsp;&nbsp;Distributions of earnings received from equity method investments |  |  | 147 |
| &nbsp;&nbsp;&nbsp;&nbsp;Income from equity method investments |  |  | (261) |
| &nbsp;&nbsp;&nbsp;&nbsp;Loss from debt investment |  |  | 1219 |
| &nbsp;&nbsp;&nbsp;&nbsp;Gain on disposal of property and equipment |  | (3004) | (332) |
| &nbsp;&nbsp;&nbsp;&nbsp;Amortization of deferred financing costs |  | 64 | 85 |
| &nbsp;&nbsp;&nbsp;&nbsp;Deferred income tax benefit |  | (1961) |  |
| Changes in working capital: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable, net |  | (1638) | (8225) |
| &nbsp;&nbsp;&nbsp;&nbsp;Inventory |  | (4) | 470 |
| &nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other assets |  | (150) | 1523 |
| &nbsp;&nbsp;&nbsp;&nbsp;Trade payables |  | 1598 | 1114 |
| &nbsp;&nbsp;&nbsp;&nbsp;Deferred revenue |  | 499 | 394 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accrued liabilities |  | (1979) | (904) |
| &nbsp;&nbsp;&nbsp;&nbsp;Income tax payable/receivable |  | (2433) | (2599) |
| **Net cash provided by operating activities** |  | $15108 | $11357 |
| **Cash flows from investing activities** |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Purchase of property and equipment |  | (23612) | (14940) |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash paid for acquisitions, net of cash acquired | 3 |  | (2999) |
| &nbsp;&nbsp;&nbsp;&nbsp;Proceeds from sale of property and equipment | 4 | 13355 | 1407 |
| **Net cash used in investing activities** |  | $(10257) | $(16532) |
| **Cash flows from financing activities** |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Proceeds from exercise of options | 8 | 1368 | 325 |
| &nbsp;&nbsp;&nbsp;&nbsp;Principal payments on term notes | 6 | (220) | (810) |
| &nbsp;&nbsp;&nbsp;&nbsp;Proceeds from revolving credit facilities | 6 |  | 3000 |
| &nbsp;&nbsp;&nbsp;&nbsp;Payments for debt issuance costs |  |  | (151) |
| &nbsp;&nbsp;&nbsp;&nbsp;Shares redeemed to pay income tax | 8 | (1631) | (972) |
| &nbsp;&nbsp;&nbsp;&nbsp;Shares repurchased under the share repurchase program |  | (1664) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Repayments of finance lease liabilities |  | (35) | (249) |
| &nbsp;&nbsp;&nbsp;&nbsp;Distributions to non-controlling interest |  | (193) |  |
| **Net cash provided by (used in) financing activities** |  | $(2375) | $1143 |
| **Net increase (decrease) in cash and cash equivalents** |  | 2476 | (4032) |
| **Cash and cash equivalents at beginning of year** |  | 17540 | 12839 |
| **Cash and cash equivalents at end of period** |  | $20016 | $8807 |
| **Supplemental disclosures of cash flow information** |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash paid during the period for interest |  | $212 | $515 |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash paid during the period for income taxes, net of refunds |  | $7059 | $3841 |
| **Supplemental disclosures of non-cash transactions** |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Equipment and other fixed asset purchases payable at end of period |  | $3955 | $2725 |
| &nbsp;&nbsp;&nbsp;&nbsp;Equipment sales receivable at end of period |  | $986 | $2187 |
| &nbsp;&nbsp;&nbsp;&nbsp;Repurchases of shares not yet settled |  | $169 | $— |

---

See accompanying notes to the condensed consolidated financial statements <br> Page 6

------

---

| |
|:---|
| **VIEMED HEALTHCARE, INC.<br>NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS** |
| ***(Tabular dollar amounts expressed in thousands of U.S. Dollars, except per share amounts)<br>(Unaudited)*** |

---

**1.&nbsp;&nbsp;&nbsp;&nbsp;Nature of Business and Operations**

Viemed Healthcare, Inc. (the "Company"), through its subsidiaries, is a provider of home medical equipment ("HME") and post-acute respiratory healthcare services in the United States. The Company's primary service offerings are focused on effective in-home treatment with clinical practitioners providing therapy and counseling to patients in their homes using cutting edge technology. The Company serves patients in all 50 states of the United States. The Company was incorporated under the Business Corporations Act (British Columbia) on December 14, 2016. The Company's registered and records office is located at Suite 2800, Park Place, 666 Burrard Street, Vancouver, British Columbia V6C 2Z7 and its corporate office is located at 625 E. Kaliste Saloom Road, Lafayette, Louisiana 70508.

The Company's common shares are traded on the Nasdaq Capital Market under the symbol "VMD".

**2. Summary of Significant Accounting Policies**

***Principles of Presentation***

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (the "SEC"). Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The accompanying condensed consolidated financial statements are unaudited, but reflect all adjustments consisting of normal recurring accruals, which, in the opinion of management, are necessary to present fairly the Company's Condensed Consolidated Balance Sheets, Condensed Consolidated Statements of Income, Condensed Consolidated Statements of Changes in Shareholders' Equity and Condensed Consolidated Statements of Cash Flows for the interim periods presented. The Company's fiscal year ends on December 31. The Condensed Consolidated Balance Sheet as of June 30, 2025 was derived from audited consolidated financial statements but does not include all disclosures required by GAAP. These condensed consolidated financial statements should be read in conjunction with the annual consolidated financial statements and the notes thereto and the report of the Company's independent registered public accounting firm included in the Company's Annual Report on Form 10-K for the year ended December 31, 2024. The nature of the Company's business is such that the results of any interim period may not be indicative of the results to be expected for the entire year.

Prior to December 31, 2024, the Company qualified as an "emerging growth company," as defined in Section 2(a) of the Securities Act of 1933, as amended, as modified by the Jumpstart our Business Startups Act of 2012, and took advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and other exemptions. As of December 31, 2024, the Company no longer qualified as an emerging growth company, and as a result is no longer exempt from the reporting requirements discussed above.

***Reporting Currency***

All values are in U.S. dollars ($ or "USD"). Tabular dollar amounts expressed in thousands of U.S. Dollars, except per share amounts.

***Basis of Consolidation***

These consolidated financial statements include the accounts of the Company and its subsidiaries in which it has a controlling financial interest. All intercompany transactions have been eliminated.

***Use of Estimates***

The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Management bases these estimates and assumptions upon historical experience, existing and known circumstances, authoritative accounting pronouncements and other factors that management believes to be reasonable. Significant areas requiring the use of management estimates relate to revenue recognition, accounts receivable, income tax provisions, the fair value of financial instruments, and goodwill. Actual results could differ from these estimates.

 <br> Page 7

------

***Segment Reporting***

The Company's chief operating decision-makers ("CODMs") are its Chief Executive Officer and Chief Operating Officer, who make resource allocation decisions and assess performance based on financial information presented on an aggregate basis. There are no segment managers who are held accountable by the chief operating decision-makers, or anyone else, for any planning, strategy and key decision-making regarding operations. The corporate office is responsible for contract negotiation with vendors and payors, corporate compliance with healthcare laws and regulations, and revenue cycle management, among other corporate supporting functions. Accordingly, the Company has a single reportable segment and operating segment structure. All expense categories on the Condensed Consolidated Statements of Income are significant and there are no other significant segment expenses that require disclosure.

***Accounts Receivable***

Accounts receivable and revenues are based on contractually agreed-upon rates for services provided, reduced by estimated adjustments. The accounts receivable are presented on the Condensed Consolidated Balance Sheets net of adjustments, including variable consideration for implicit price concessions related to sales revenues and an estimate for probable losses related to net rental revenues. Inherent in these estimates is the risk that they will have to be revised or updated as additional information becomes available. The complexity of third-party billing arrangements and laws and regulations governing Medicare and Medicaid may result in adjustments to amounts originally recorded.

The Company performs a periodic analysis to review the valuation of accounts receivable and collectability of outstanding balances. These estimates are determined utilizing historical realization data under a portfolio approach, which is then assessed by management to evaluate whether adjustments should be made based on accounts receivable aging trends, other operating trends, and relevant business conditions such as governmental and managed care payor claims processing procedures.

The Company records a reserve for estimated probable losses as part of rental revenue adjustments in order to report rental revenue at an expected collectable amount based on the total portfolio of operating lease receivables for which collectability has been deemed probable.

Receivables are considered past due when not collected by established due dates. Specific patient balances are written off after collection efforts have been followed and the account has been determined to be uncollectible. Revisions in reserve estimates are recorded as an adjustment to revenue in the period of revision.

Included in accounts receivable at June 30, 2025 are amounts due from Medicare representing 28% of total outstanding net receivables. As of December 31, 2024, 27% of total outstanding net receivables were amounts due from Medicare.

***Inventory***

Inventory represents non-serialized supplies that consist of equipment parts, consumables, and associated product supplies and is expensed at the time of sale or use. The Company values inventory at the lower of cost or net realizable value. Obsolete and unserviceable inventories are valued at estimated net realizable value.

***Property and Equipment***

Property and equipment is presented on the Condensed Consolidated Balance Sheets at historic cost less accumulated depreciation. Major renewals and improvements that extend the useful life of assets are capitalized to the respective property accounts, while maintenance and repairs, which do not extend the useful life of the respective assets, are expensed as incurred. Management has estimated the useful lives of equipment leased to customers. Depreciation is computed using the straight-line method over the estimated useful lives of the respective assets. Property and equipment are depreciated on a straight-line basis over their estimated useful lives.

Depreciation of medical equipment commences at the date of service, which represents the date that the asset has been delivered to a patient and is put in use and continues through the useful life of the asset. Property and equipment with definite useful lives are tested for impairment whenever events or changes in circumstances indicate that their carrying amount may not be recoverable.

 <br> Page 8

------

***Equity Investments***

Equity investments on the Condensed Consolidated Balance Sheets are primarily comprised of equity investments without readily determinable fair values accounted for under the measurement alternative described in ASC 321-10-35-2. For these investments, the Company has elected the measurement alternative which measures the investment at cost, less any impairment. ASU 2019-04 clarifies that if an entity identifies observable price changes in orderly transactions for the identical or a similar investment of the same issuer, it must measure its equity investment at fair value in accordance with ASC 820 as of the date that the observable transaction occurred. The balance of the Company's equity investments was $2.8 million as of June 30, 2025 and December 31, 2024. The Company was not aware of any impairment or observable price change adjustments that needed to be made as of June 30, 2025 on its investments in equity securities without a readily determinable fair value.

***Intangible Assets***

Intangible assets include trade names and other identifiable intangible assets. Amortization expense related to definite lived identifiable intangible assets is included in depreciation and amortization in the accompanying Condensed Consolidated Statements of Income.

***Revenue Recognition***

Revenues are principally derived from the rental and sale of HME products and services to patients.

*Rental revenues*

Revenue generated from equipment that is rented to patients is recognized over the non-cancellable rental period (typically one month) and commences on delivery of the equipment to the patients. The agreements are evaluated at commencement and the start of each monthly renewal period to determine if it is reasonably certain that the monthly renewal or purchase options would be exercised. The exercise of monthly renewal or purchase options by a patient has historically not been reasonably certain to occur at lease commencement or subsequent monthly renewals.

Revenues are recorded at amounts estimated to be received under reimbursement arrangements with payors, including private insurers, prepaid health plans, Medicare, Medicaid and patients. Rental revenue, less estimated adjustments, is recognized as earned on a straight-line basis over the non-cancellable lease term. Rental of patient equipment is billed on a monthly basis beginning on the date the equipment is delivered. Since deliveries can occur on any day during a month, the amount of billings that apply to the next month are deferred.

The Company's lease agreements generally contain lease components and non-lease components, which primarily relate to supplies. The Company has made the accounting policy election to account for a lease component of an agreement and its associated non-lease components as a single lease component based on the Company's assessment of classification of the lease based on the consideration in the contract for the combined component.

*Sales and Services revenues*

Revenue related to sales of equipment and supplies is recognized on the date of delivery as this is when control of the promised goods is transferred to patients and is presented net of applicable sales taxes. Revenues are recorded only to the extent it is probable that a significant reversal will not occur in the future as amounts may include implicit price concessions under reimbursement arrangements with payors, including private insurers, prepaid health plans, Medicare, Medicaid and patients. The sales transaction price is determined based on contractually agreed-upon rates, adjusted for estimates of variable consideration. The expected value method is used in determining the variable consideration as part of determining the sales transaction price using historical reimbursement experience, historical sales returns, and other operating trends. Payment terms and conditions vary by contract. The timing of revenue recognition, billing, and cash collection generally results in billed and unbilled accounts receivable.

Revenues associated with external staffing services are accrued on an hourly basis and are recorded based on the determination of whether the Company is acting as a principal or an agent. In arrangements in which the Company manages customers' supplemental workforce needs utilizing its own network of healthcare professionals, the Company is determined to be a principal and includes the contractual gross billings in revenues with a corresponding increase to cost of revenues for worksite employee payroll costs associated with these services. Alternatively, when the Company acts as agent in the performance of workforce management, revenue is recorded based on contractually agreed upon fees or commissions with no associated cost of revenues.

 <br> Page 9

------

The revenues from each major source are summarized in the following table:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended June 30,** | **Three Months Ended June 30,** | **Six Months Ended June 30,** | **Six Months Ended June 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| ***Revenue from rentals*** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Ventilator rentals, non-invasive and invasive | $33819 | $30445 | $65979 | $59632 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other home medical equipment rentals | 13823 | 12211 | 26798 | 23145 |
| ***Revenue from sales and services***  |  |  |  |  |
| Equipment and supply sales | 9514 | 7378 | 17020 | 13516 |
| *&nbsp;&nbsp;&nbsp;&nbsp;*Service revenues | 5900 | 4931 | 12388 | 9265 |
| **Total revenues** | $**63056** | $**54965** | $**122185** | $**105558** |

---

Revenues from Medicare as a percentage of the Company's total revenue for the six months ended June 30, 2025 and 2024 were 40% and 43%, respectively.

***Stock-Based Compensation***

The Company accounts for its stock-based compensation in accordance with ASC 718*, "Compensation—Stock Compensation"*, which establishes accounting for share-based awards exchanged for employee services and requires companies to expense the estimated fair value of these awards over the requisite employee service period. Stock–based compensation costs for stock options are determined at the grant date using the Black-Scholes option pricing model. Stock-based compensation costs for restricted stock units ("RSUs") are determined at the grant date based on the closing stock price. The expense of such stock-based compensation awards is recognized using the graded vesting attribution method over the vesting period and the offsetting credit is recorded as an increase in additional paid-in capital. Forfeitures are recorded as incurred. Any excess tax benefit or deficiency is recognized as a component of income taxes and within operating cash flows upon vesting of the share-based award.

For the Company's phantom share units ("PSUs") settled in cash, the Company computes the fair value of the PSUs using the closing price of the Company's stock at the end of each period and records a liability based on the percentage of requisite service.

***Income Taxes***

The Company is subject to income taxes in numerous U.S. jurisdictions. The Company's income tax provisions reflect management's interpretation of country and state tax laws. There are many transactions and calculations for which the ultimate tax determination is uncertain during the ordinary course of business and may remain uncertain for several years after their occurrence. The Company recognizes assets and liabilities for taxation when it is probable that the Company will receive refunds from or pay taxes to the relevant tax authority. Where the final determination of tax assets and liabilities is different from the amounts that were initially recorded, such differences will impact the current and deferred income taxes provision in the period in which such a determination is made. Changes in tax law or changes in the way tax law is interpreted may also impact the Company's effective tax rate as well as the Company's business and operations.

Deferred income tax assets and liabilities are recognized for the future income tax consequences attributable to temporary differences between the financial statement carrying value of assets and liabilities and their respective income tax bases. Deferred income tax assets or liabilities are measured using enacted income tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be settled. The calculation of current and deferred income taxes requires management to make estimates and assumptions and to exercise a certain amount of judgment concerning the carrying value of assets and liabilities. The current and deferred income tax assets and liabilities are also impacted by expectations about future operating results and the timing of reversal of temporary differences as well as possible audits of tax filings by regulatory agencies. Changes or differences in these estimates or assumptions may result in changes to the current and deferred tax assets and liabilities on the Condensed Consolidated Balance Sheets and a charge to or recovery of income tax expense.

Deferred tax is recognized on any temporary differences between the carrying amounts of assets and liabilities in the consolidated financial statements and the corresponding tax bases used in the computation of taxable earnings. The effect of a change in the enacted tax rates is recognized in net earnings and comprehensive income or in equity depending on the item to which the adjustment relates. At each reporting period end, deferred tax assets are evaluated for recoverability based on whether it is more likely than not that sufficient taxable earnings will be available to allow all or part of the asset to be recovered.

 <br> Page 10

------

**Business Combinations**

The Company applies the acquisition method of accounting for business acquisitions. The results of operations of the business acquired by the Company are included as of the respective acquisition date. The acquisition-date fair value of the consideration transferred, including the fair value of any contingent consideration, is allocated to the underlying assets acquired, liabilities assumed, and noncontrolling interest in the acquiree based upon their estimated fair values at the date of acquisition. To the extent the acquisition-date fair value of the consideration transferred exceeds the fair value of the identifiable tangible and intangible assets acquired, liabilities assumed, and any noncontrolling interests, such excess is allocated to goodwill. Patient relationships, medical records and patient lists are not reported as separate intangible assets due to the regulatory requirements and lack of contractual agreements but are part of goodwill. Customer related relationships are not reported as separate intangible assets but are part of goodwill as authorizing physicians are under no obligation to refer the Company's services to their patients, who are free to change physicians and service providers at any time. The Company may adjust the preliminary purchase price allocation, as necessary, as it obtains more information regarding asset valuations and liabilities assumed that existed but were not available at the acquisition date, which is generally up to one year after the acquisition closing date. Acquisition related costs are recognized separately from the business combination and are expensed as incurred.

**Impairment of Goodwill and Long-Lived Assets**

Goodwill resulting from business combinations is not amortized, rather, it is assessed for impairment annually and upon the occurrence of a triggering event or change in circumstances indicating a possible impairment. Such triggering events potentially warranting an annual or interim goodwill impairment assessment include, among other factors, declines in historical or projected revenue, operating income or cash flows, and sustained decreases in the Company's stock price or market capitalization. Such changes in circumstance can include, among others, changes in the legal environment, reimbursement environment, operating performance, and/or future prospects.

The Company performs its annual impairment assessment of goodwill during the fourth quarter of each year. The impairment assessment can be performed on either a quantitative or qualitative basis. The Company first assesses qualitative factors to determine whether it is necessary to perform a quantitative goodwill impairment analysis. If determined necessary, the Company applies the quantitative impairment test to identify and measure the amount of impairment, if any. Fair value determinations require considerable judgment and are sensitive to changes in underlying assumptions and factors, such as estimates of a reporting unit's fair value and judgment about impairment triggering events. As a result, there can be no assurance that the estimates and assumptions made for purposes of the annual or interim goodwill impairment test will prove to be accurate predictions of the future.

For the year ended December 31, 2024, the Company performed an assessment of qualitative factors and determined that no events or circumstances existed that would lead to a determination that it is more likely than not that the fair value of indefinite-lived assets were less than the carrying amount. As such, a quantitative analysis was not required to be performed and the Company did not record any goodwill impairment charges.

The Company follows ASC Topic 360, which requires that long-lived assets be reviewed for impairment whenever events or changes in circumstances indicate that the asset group's carrying amounts may not be recoverable. In performing the review for recoverability, if future undiscounted cash flows (excluding interest charges) from the use and ultimate disposition of the assets are less than their carrying values, an impairment loss represented by the difference between its fair value and carrying value, is recognized. When properties are classified as held for sale, they are recorded at the lower of the carrying amount or the expected sales price less costs to sell. There were no impairment charges recognized during the six months ended June 30, 2025 and June 30, 2024.

**Net Income per Share Attributable to Viemed Healthcare, Inc.'s Common Stockholders**

Basic net income per share is computed based on the weighted average number of shares of common stock outstanding during the period. Diluted net income per common share is computed based on the weighted average number of shares of common stock plus the effect of dilutive stock-based awards outstanding during the period using the treasury stock method. Dilutive stock-based awards include outstanding common stock options and time-based RSUs.

See Note 11 for earnings per share computations.

 <br> Page 11

------

***Recently Adopted Accounting Pronouncements***

In November 2023, the Financial Accounting Standards Board ("FASB") issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires a public entity to disclose significant segment expenses and other segment items on an annual and interim basis and to provide in interim periods all disclosures about a reportable segment's profit or loss and assets that are currently required annually. Public entities with a single reportable segment are required to provide the new disclosures and all the disclosures required under ASC 280. The ASU is effective for fiscal years beginning after December 15, 2023 and interim periods beginning after December 15, 2024. The guidance is applied retrospectively to all periods presented in the financial statements, unless it is impracticable. The Company adopted this standard during the year ended December 31, 2024, which did not have a material impact on its consolidated financial statements and related disclosures.

***Recently Issued Accounting Pronouncements***

In December 2023, the FASB issued Accounting Standards Update (ASU) No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which is intended to improve the transparency of income tax disclosures by requiring consistent categories and greater disaggregation of information in the effective tax rate reconciliation and income taxes paid by jurisdiction. The ASU is effective for public business entities' annual periods beginning after December 15, 2024, with early adoption permitted. The Company adopted this pronouncement and is evaluating the impact it will have on its upcoming annual filing on Form 10-K for the year ended December 31, 2025; however, the Company currently does not believe the adoption will have a material impact on its consolidated financial statements and disclosures for that Form 10-K filing.

In November 2024, the FASB issued ASU 2024-03, Disaggregation of Income Statement Expenses (DISE), which specifies additional disclosure requirements. The new guidance requires additional disclosures, including the composition of certain income expense line items (such as purchases of inventory, employee compensation, and 'other expenses') and a separate disclosure for selling expenses. This ASU is effective for fiscal years beginning after December 15, 2026, and interim periods beginning after December 15, 2027, however, early adoption is permitted. The Company is currently evaluating the impact of adopting this guidance on its consolidated financial statements.

**3. &nbsp;&nbsp;&nbsp;&nbsp;Business Combinations**

***East Alabama HomeMed, LLC***

On April 1, 2024, the Company acquired a controlling 60% equity interest in East Alabama HomeMed, LLC ("HomeMed"). The acquisition was accounted for under the acquisition method of accounting in accordance with ASC 805. As a result of the acquisition, goodwill of $3.2 million and a trade name of $0.4 million were recognized. The Company determined that its portion of the goodwill is fully tax-deductible. Additionally, a noncontrolling interest of $1.8 million was recorded at the acquisition date. The accompanying financial statements include the results of HomeMed's operations from the acquisition date. Changes in the noncontrolling interests after the acquisition date are accounted for pursuant to ASC 810, *Consolidation*.

**4. &nbsp;&nbsp;&nbsp;&nbsp;Property and Equipment**

The Company's fixed assets consist of its medical equipment held for rental, furniture and equipment, real property and related improvements, and vehicles and other various small equipment.

The following table details the Company's fixed assets:

---

| | | |
|:---|:---|:---|
| | **June 30, 2025** | **December 31, 2024** |
| Medical equipment | $116058 | $116938 |
| Furniture and equipment | 4845 | 4523 |
| Land | 2566 | 2566 |
| Buildings | 8429 | 8307 |
| Leasehold improvements | 648 | 660 |
| Vehicles | 1279 | 1288 |
| Less: Accumulated depreciation | (54090) | (58003) |
| **Property and equipment, net of accumulated depreciation** | $**79735** | $**76279** |

---

 <br> Page 12

------

Depreciation in the amount of $6.5 million and $5.9 million is included in cost of revenue for the three months ended June 30, 2025 and 2024, respectively, and in the amount of $12.8 million and $11.8 million for the six months ended June 30, 2025 and 2024, respectively.

**5. &nbsp;&nbsp;&nbsp;&nbsp;Current Liabilities**

The Company's short-term accrued liabilities are included within current liabilities and consist of the following:

---

| | | |
|:---|:---|:---|
| | **June 30, 2025** | **December 31, 2024** |
| Accrued trade payables | $4343 | $4016 |
| Accrued commissions payable | 1085 | 1027 |
| Accrued bonuses payable | 4474 | 6589 |
| Accrued vacation and payroll | 3488 | 3402 |
| Current portion of phantom share liability | 1092 | 1701 |
| Accrued other liabilities | 4162 | 3422 |
| **Total accrued liabilities** | $**18644** | $**20157** |

---

**6. &nbsp;&nbsp;&nbsp;&nbsp;Debt and Lease Liabilities**

**Debt**

The following table summarizes the Company's debt as of June 30, 2025 and December 31, 2024:

---

| | | |
|:---|:---|:---|
| | **June 30, 2025** | **December 31, 2024** |
| 2022 Senior Credit Facilities | $4375 | $4563 |
| Medical equipment financing | 445 | 34 |
| Financing costs and commitment fees | (535) | (599) |
| Current portion | (820) | (409) |
| **Long-term portion** | $**3465** | $**3589** |

---

**2022 Senior Credit Facilities**

On November 29, 2022, the Company refinanced its existing borrowings under the 2018 Senior Credit Facility and entered into a new credit agreement (the "2022 Senior Credit Facilities") with the lenders from time to time party thereto, and Regions Bank, as administrative agent (the "Administrative Agent") and collateral agent, that provides for an up to $30.0 million revolving credit facility (the "2022 Revolving Credit Facility") and an up to $30.0 million delayed draw term loan facility (the "2022 Term Loan Facility"), both maturing in November 2027.

The proceeds of the 2022 Revolving Credit Facility may be used to refinance existing indebtedness, for working capital purposes, capital expenditures and other general corporate purposes (including permitted acquisitions), and to pay transaction fees, costs and expenses related to the 2022 Senior Credit Facilities. The proceeds of the 2022 Term Loan Facility and any additional term loans established in accordance with the 2022 Senior Credit Facilities may be used to finance permitted acquisitions and to pay transaction fees, costs and expenses related to such acquisitions.

The interest rates per annum applicable to the 2022 Senior Credit Facilities are a forward looking term rate based on a secured overnight financing rate ("Term SOFR") plus an applicable margin ranging from 2.625% to 3.375%, or, at the option of the Company, a Base Rate (as defined in the 2022 Senior Credit Facilities) plus an applicable margin, which ranges from 1.625% to 2.375%.

 <br> Page 13

------

The 2022 Senior Credit Facilities require the Company to comply with certain affirmative, as well as certain negative covenants that, among other things, restrict, subject to certain exceptions, the ability of the Company to incur indebtedness, grant liens, make investments, engage in acquisitions, mergers or consolidations and pay dividends and other restricted payments. The 2022 Senior Credit Facilities also include certain financial covenants, which generally include, but are not limited to the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Consolidated Total Leverage Ratio (defined generally as total indebtedness to adjusted EBITDA) of not greater than (i) for any fiscal quarter ending during the period from the closing date to and including December 31, 2024, 2.75 to 1.0 and (ii) for any fiscal quarter ending on and after March 31, 2025, 2.50 to 1.0, subject to certain adjustments following a material acquisition.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Consolidated Fixed Charge Coverage Ratio (defined generally as (a) adjusted EBITDA minus capital expenditures minus cash taxes to (b) the sum of scheduled principal payments plus cash interest expense plus restricted payments) of not less than 1.25:1.0.

The Company was in compliance with all covenants under the 2022 Senior Credit Facilities in effect at June 30, 2025.

The 2022 Senior Credit Facilities include provisions permitting the Company from time to time to, subject to certain terms and conditions, increase the aggregate amount of commitments under the 2022 Revolving Credit Facility and/or establish one or more additional term loans under the 2022 Term Loan Facility, in each case, with additional commitments from existing lenders or new commitments from financial institutions acceptable to the Administrative Agent in its reasonable discretion; provided, that, (a) the aggregate principal amount of any increases in the 2022 Revolving Credit Facility, and (b) the aggregate principal amount of all additional term loans under the 2022 Term Loan Facility established after the closing date will not exceed $30.0 million.

Financing costs related to the 2022 Senior Credit Facilities are capitalized and amortized over the term of the loans using the effective interest method. Upon the initial draw of debt under the 2022 Senior Credit Facilities during the year ended December 31, 2023, the Company reclassified the deferred financing fees previously recorded in other long-term assets to long-term debt in the condensed consolidated balance sheets.

On May 28, 2024, the Company entered into a First Amendment to the 2022 Senior Credit Facilities that (a) extended the delayed draw term loan commitment expiration date to November 29, 2025, from its initial expiration date of May 29, 2024, and (b) provided for other technical amendments. On June 6, 2025, the Company entered into a Second Amendment to the 2022 Senior Credit Facilities that (a) increased the permitted amount of restricted payments that may be made by the Company and its subsidiaries subject to specified conditions, and (b) made other conforming and administrative changes.

**Medical Equipment Financing**

The Company enters into medical equipment financing obligations through supplier finance programs. The financing obligations are primarily short term in nature and are payable in monthly installments.

**Leases**

The Company has recognized finance lease liabilities for vehicles and operating leases for land and buildings that have terms greater than twelve months, as follows:

---

| | | |
|:---|:---|:---|
| | **June 30, 2025** | **December 31, 2024** |
| Lease liabilities | $2605 | $2868 |
| Less: |  |  |
| Current portion of lease liabilities | (910) | (861) |
| **Net long-term lease liabilities** | $**1695** | $**2007** |

---

**Operating Lease Liabilities**

The Company has recognized operating lease liabilities that relate primarily to the lease of land and buildings. The exercise of lease renewal options is at the Company's sole discretion and is included in the lease term for calculations of its right-of-use assets and liabilities when it is reasonably certain that the Company plans to renew these leases. These lease liabilities are recorded at present value based on a discount rate ranging from 5.5% to 7.87%, based on the Company's incremental borrowing rate at the time of assessment. At June 30, 2025, the weighted average lease term was approximately 3.02 years.

 <br> Page 14

------

Future maturities of the Company's operating lease liabilities as of June 30, 2025 are summarized as follows:

---

| | |
|:---|:---|
| | **Lease Liability** |
| 2025 | $514 |
| 2026 | 1022 |
| 2027 | 791 |
| 2028 | 583 |
| 2029 | 3 |
| Thereafter | 3 |
| Total lease payments | $2916 |
| Less: imputed interest | 326 |
| **Present value of lease liabilities** | $**2590** |

---

Operating rental expenses were $0.8 million and $0.7 million during the six months ended June 30, 2025 and June 30, 2024, respectively.

**7. &nbsp;&nbsp;&nbsp;&nbsp;Fair Value Measurement**

Under ASC Topic 820, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (i.e., an exit price). ASC Topic 820 establishes a hierarchy for inputs to valuation techniques used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. There are three levels to the hierarchy based on the reliability of inputs, as follows:

Level 1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.

Level 2 - Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs include quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets and liabilities in markets that are not active.

Level 3 - Unobservable inputs for the asset or liability. The degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3.

**Assets Measured at Fair Value on a Recurring Basis**

The Company measures certain assets at fair value on a recurring basis. There were no transfers between fair value measurement levels during any presented period. The following tables summarize the Company's assets measured at fair value on a recurring basis as of June 30, 2025 and December 31, 2024:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **At June 30, 2025** | **At June 30, 2025** | **At June 30, 2025** | **At June 30, 2025** |
|<br>(In thousands) | **Level 1** | **Level 2** | **Level 3** | **Total** |
| **Recurring Fair Value Measurements:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Money market mutual funds | $4277 | $— | $— | $4277 |
| **Total** | $**4277** | $**—** | $**—** | $**4277** |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **At December 31, 2024** | **At December 31, 2024** | **At December 31, 2024** | **At December 31, 2024** |
|<br>(In thousands) | **Level 1** | **Level 2** | **Level 3** | **Total** |
| **Recurring Fair Value Measurements:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Money market mutual funds | $10582 | $— | $— | $10582 |
| **Total** | $**10582** | $**—** | $**—** | $**10582** |

---

 <br> Page 15

------

**Assets and Liabilities Measured at Fair Value on a Nonrecurring Basis**

The Company measures certain assets at fair value on a nonrecurring basis. These assets include other equity investments and the fair value allocation related to the Company's acquisitions.

The Company's other equity investments are holdings in privately-held companies without a readily determinable market value. The Company remeasures equity securities without readily determinable fair value at fair value when an orderly transaction is identified for an identical or similar investment of the same issuer in accordance with the measurement alternative under Topic 820. ASU 2019-04 states that the measurement alternative is a nonrecurring fair value measurement. Accordingly, other equity investments without readily determinable fair value are classified within Level 3 in the fair value hierarchy because the Company estimates the value using a combination of observable and unobservable inputs, including valuation ascribed to the issuing company in subsequent financing rounds, volatility in the results of operations of the issuers and rights and obligations of the holdings the Company owns. The Company had no material adjustments of other equity investments measured at fair value on a nonrecurring basis during any of the periods presented.

The fair value allocation related to the Company's acquisitions are determined using a discounted cash flow approach, or a replacement cost approach, which are based on significant unobservable inputs (Level 3). These valuation methods required management to make various assumptions, including, but not limited to, future profitability, cash flows, replacement costs, and discount rates. The Company's estimates are based upon historical trends, management's knowledge and experience and overall economic factors, including projections of future earnings potential. Developing discounted future cash flows in applying the income approach requires the Company to evaluate its intermediate to longer-term strategies, including, but not limited to, estimates of revenue growth, operating margins, capital requirements, inflation and working capital management. The development of appropriate rates to discount the estimated future cash flows requires the selection of risk premiums, which can materially impact the present value of future cash flows.

The Company estimated the fair value of acquired identifiable intangible assets using discounted cash flow techniques that included an estimate of future cash flows, consistent with overall cash flow projections used to determine the purchase price paid to acquire the business, discounted at a rate of return that reflects the relative risk of the cash flows. The Company estimated the fair value of certain acquired identifiable intangible assets based on the cost approach using estimated costs consistent with historical experience. The Company believes the estimates and assumptions used in the valuation methods are reasonable.

There were no transfers between fair value measurement levels during any presented period.

 <br> Page 16

------

**8. &nbsp;&nbsp;&nbsp;&nbsp;Shareholders' Equity**

***Authorized Share Capital***

The Company's authorized share capital consists of an unlimited number of common shares, with no stated par value.

***Issued and Outstanding Share Capital***

The Company has only one class of stock outstanding, common shares. The authorized stock consists of an unlimited number of common shares with no stated par value, of which 39,605,005 and 39,132,897 shares were issued and outstanding as of June 30, 2025 and December 31, 2024, respectively.

For the six months ended June 30, 2025, the Company repurchased and canceled 270,061 common shares at a cost of $1.8 million pursuant to the Share Repurchase Program authorized by the Board of Directors on June 6, 2025 (the "2025 Share Repurchase Program"). The Company also acquired and cancelled 199,820 common shares at a cost of $1.6 million to satisfy employee income tax withholding associated with RSUs vesting during the six months ended June 30, 2025. The Company's equity accounts were reduced by the amount paid for the shares repurchased and cancelled.

***Stock-Based Compensation***

On June 6, 2024 (the "Effective Date"), the Company's shareholders approved the Company's 2024 Long Term Incentive Plan (the "2024 Omnibus Plan") to provide an incentive to attract, retain, and reward directors, officers, employees, and consultants who provide services to the Company or any of its subsidiaries. All directors, officers, employees, and consultants of the Company and/or its affiliates are eligible to receive awards under the 2024 Omnibus Plan, subject to its terms. Awards include common share purchase options, restricted stock, stock appreciation rights, performance awards, or other stock-based awards, including restricted stock units, deferred stock units, and dividends and dividend equivalents.

On June 5, 2025, the Company's shareholders approved the first amendment to the 2024 Omnibus Plan, increasing the aggregate number of common shares authorized for issuance. Following this amendment, the maximum number of common shares that will be available for awards and issuance under the 2024 Omnibus Plan and that may be reserved for issuance at any time, including under previous plans such as the 2020 Long Term Incentive Plan (effective June 11, 2020), the Amended and Restated Stock Option Plan (effective as of July 17, 2018), the Amended and Restated Restricted Share Unit Plan (effective as of July 17, 2018), and the Deferred Share Unit Plan (effective July 17, 2018), is 7,904,769 shares. The maximum amount of common shares that may be awarded under the 2024 Omnibus Plan as "incentive stock options" is 1,000,000 common shares. As of June 30, 2025, the Company had outstanding options of 3,552,000 and RSUs of 2,187,000 associated with common shares under the existing plans.

The following table summarizes stock-based compensation expense for the three and six months ended June 30, 2025 and 2024 (in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended June 30,** | **Three Months Ended June 30,** | **Six Months Ended June 30,** | **Six Months Ended June 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| Stock-based compensation - options | $6 | $59 | $22 | $170 |
| Stock-based compensation - restricted stock units | 2335 | 1561 | 4630 | 2882 |
| **Total** | $**2341** | $**1620** | $**4652** | $**3052** |

---

At June 30, 2025, there was approximately $3,000 of total unrecognized pre-tax stock option expense under the Company's equity compensation plans, which is expected to be recognized over a weighted-average period of 0.15 years. As of June 30, 2025, there was approximately $9,991,000 of total unrecognized pre-tax compensation expense related to outstanding time-based restricted stock units that is expected to be recognized over a weighted-average period of 1.56 years.

 <br> Page 17

------

***Options***

The following table summarizes stock option activity for the six months ended June 30, 2025:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Number of options<br> (000's)** | **Weighted average exercise price**<sup>(1)</sup> | **Weighted average remaining contractual life** | **Aggregate intrinsic value**<sup>(2)</sup> |
| **Balance December 31, 2024** | **3917** | $**5.36** | **5.0 years** | $**10984** |
| Issued |  |  |  |  |
| Exercised | (339) | 4.04 |  |  |
| Expired / Forfeited | (26) | 10.44 |  |  |
| **Balance June 30, 2025** | **3552** | $**5.45** | **4.7 years** | $**6570** |

---

<sup>(1)</sup> For presentation purposes, stock options issued with a Canadian dollar exercise price have been translated to U.S. dollars based on the prevailing exchange rate on the date of grant.

<sup>(2)</sup> The aggregate intrinsic value of options outstanding represents the difference between the exercise price of the option and the closing price of the Company's common shares on the last trading day of the period ($6.91 and $8.02 on June 30, 2025 and December 31, 2024, respectively).

The aggregate intrinsic value of options outstanding was $6,570,000 and options exercisable was $6,560,000 at June 30, 2025. For the six months ended June 30, 2025, 338,858 common shares were issued pursuant to the exercise of stock options.

At June 30, 2025, the Company had 3,535,000 exercisable stock options outstanding with a weighted average exercise price of $5.45 and a weighted average remaining contractual life of 4.6 years. At December 31, 2024, the Company had 3,691,000 exercisable stock options outstanding with a weighted average exercise price of $5.37 and a weighted average remaining contractual life of 4.9 years.

The fair value of the stock options has been charged to the Condensed Consolidated Statements of Income and credited to additional paid-in capital over the vesting period, using the grant date fair value based on the Black-Scholes option pricing model. The assumptions used to determine the grant date fair value of stock options include exercise price, risk-free interest rates, expected volatility, and average life of an option. The risk-free interest rates are based on the rates available at the time of the grant for zero-coupon U.S. government issues with a remaining term equal to the option's expected life. The average life of an option is based on both historical and projected exercise and lapsing data. Expected volatility is based on implied volatilities from traded options on the Company's common shares and historical volatility of the Company's common shares over the expected life of the option. There were no issuances of options during the six months ended June 30, 2025.

***Restricted Stock Units***

The Company accounts for RSUs using fair value. The fair value of the RSUs has been charged to the Condensed Consolidated Statements of Income and credited to additional paid-in capital over the vesting period, based on the stock price on the date of grant. RSUs vest generally over a one or three-year period. The Company accounts for forfeitures of RSUs under ASU 2016-09 and recognizes forfeitures in the period in which they occur.

The following table summarizes RSU activity for the six months ended June 30, 2025:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Number of RSUs (000's)** | **Weighted average grant price** | **Weighted average remaining contractual life** | **Aggregate intrinsic value**<sup>(1)</sup> |
| **Balance December 31, 2024** | **1514** | $**7.80** | **1.38 years** | $**12141** |
| Issued | 1292 | 8.15 |  |  |
| Vested | (603) | 7.46 |  |  |
| Forfeited | (16) | 7.31 |  |  |
| **Balance June 30, 2025** | **2187** | $**8.10** | **1.56 years** | $**15109** |

---

<sup>(1)</sup> The aggregate intrinsic value of time-based RSUs outstanding was based on the closing price of the Company's common shares on the last trading day of the period ($6.91 and $8.02 on June 30, 2025 and December 31, 2024, respectively).

During the six months ended June 30, 2025, the Company issued 1,291,631 RSUs with vestings over a three year period and a fair value of $8.15 per share.

 <br> Page 18

------

***Phantom Share Units***

The Company has a phantom share unit plan, which it uses for grants to directors, officers, and employees. PSUs granted under the plan are non-assignable and are settled in cash at vesting based on the fair value of the Company's common stock on the vesting date. PSUs vest annually over a three-year period. The cash-settled PSUs are accounted for as liability awards and are re-measured at fair value each reporting period until they become vested with accrued liability and related expense being recognized over the requisite service period.

The following table summarizes PSU activity for the six months ended June 30, 2025:

---

| | | |
|:---|:---|:---|
| | **Number of phantom share units (000's)** | **Value of share equivalents**<sup>(1)</sup> |
| **Balance December 31, 2024** | **441** | $**3537** |
| Issued | 261 | 2164 |
| Vested | (207) | 1641 |
| Forfeited | (1) | (9) |
| **Balance June 30, 2025** | **494** | $**3414** |

---

<sup>(1)</sup> The value of outstanding share equivalents at the beginning of the period is based on the market price of the Company's common shares at that time, the value of issued share equivalents is based on the market price of the Company's common shares at issuance, the value of vested share equivalents is based on the cash paid at the time of vesting, and the values of forfeited share equivalents and outstanding share equivalents at the end of the period are based on the market price of the Company's common shares at the end of the period. The market price of the Company's common shares was $6.91 and $8.02 on June 30, 2025 and December 31, 2024, respectively.

The change in fair value of the PSUs has been charged to the Condensed Consolidated Statements of Income and recorded as a liability included in accrued liabilities and long-term accrued liabilities. The total liability associated with PSUs at June 30, 2025 is $1.6 million, with $1.1 million of this amount included in current accrued liabilities and the remaining portion of $0.5 million included in long-term accrued liabilities.

The impact associated with the fair value re-measurement of PSUs is recorded in selling, general and administrative expenses within the unaudited Condensed Consolidated Statements of Income. The following table summarizes expense (benefit) associated with the PSUs for the three and six months ended June 30, 2025 and 2024 (in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended June 30,** | **Three Months Ended June 30,** | **Six Months Ended June 30,** | **Six Months Ended June 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| Selling, general, and administrative | $370 | $(287) | $781 | $553 |

---

The Company paid cash settlements of $1.6 million during each of the six months ended June 30, 2025 and 2024 pertaining to vestings of cash-settled PSUs.

**9. &nbsp;&nbsp;&nbsp;&nbsp;Commitments and Contingencies**

The Company accrues estimates for resolution of any legal and other contingencies when losses are probable and reasonably estimable in accordance with ASC 450, Contingencies ("ASC 450"). No less than quarterly, the Company reviews the status of each significant matter underlying a legal proceeding or claim and assess our potential financial exposure. The Company accrues a liability for an estimated loss if the potential loss from any legal proceeding or claim is considered probable and the amount can be reasonably estimated. Significant judgment is required in both the determination of probability and the determination as to whether the amount of an exposure is reasonably estimable, and accruals are based only on the information available to the Company at the time the judgment is made, which may prove to be incomplete or inaccurate or unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions. Furthermore, the outcome of legal proceedings is inherently uncertain, and we may incur substantial defense costs and expenses defending any of these matters.

 <br> Page 19

------

***Legal Proceedings***

As previously disclosed, on November 5, 2020, the Company (through its subsidiary Sleep Management LLC) filed a lawsuit against Vyaire Medical, Inc. d/b/a CareFusion Respiratory Technologies ("Vyaire") in the 15th Judicial District Court for the Parish of Lafayette, Louisiana (the "State Court") seeking damages for breach of contract and seeking declaratory judgment. The State Court issued an order on September 5, 2023 granting the Company Partial Summary Judgment finding that Vyaire breached the contract. On June 9, 2024, Vyaire and certain of its affiliates filed voluntary bankruptcy under Chapter 11 of the Bankruptcy Code in the US Bankruptcy Court for the District of Delaware (the "Bankruptcy Court"). A liquidation analysis subsequently submitted to the Bankruptcy Court disclosed that unsecured claims, including those subordinate to the super-priority claims of certain Vyaire creditors, would not receive any recovery under the proposed Chapter 11 reorganization plan or in the event of a Chapter 7 liquidation. Consequently, collection of the Company's unsecured claim against Vyaire was determined to be not probable. During the year ended December 31, 2024, outstanding funds receivable in the amount of $0.9 million related to undelivered respiratory equipment were impaired through Other expense (income).

***Governmental and Regulatory Matters***

From time to time the Company is involved in various external governmental investigations, audits and reviews. Reviews, audits and investigations of this sort can lead to government actions, which can result in the assessment of recoupment of reimbursement, civil or criminal fines or penalties, or other sanctions, including restrictions or changes in the way the Company conducts business, loss of licensure or exclusion from participation in government healthcare programs.

**10.** &nbsp;&nbsp;&nbsp;&nbsp;**Income Taxes**

For the six months ended June 30, 2025, the Company recorded income tax expense of $2.7 million, which includes a discrete tax benefit of less than $0.1 million associated with stock-based compensation arrangements. Excluding the impact of the discrete taxes, the effective rate for the six months ended June 30, 2025 is 31.7%. The effective rate differs from the amount computed by applying the statutory federal and state income tax rates to ordinary income before the provision for income taxes due to permanent non-deductible differences. The Company's effective tax rate is based on forecasted annual results which may fluctuate significantly through the rest of the year.

At June 30, 2025 and 2024, the Company had no amounts recorded for uncertain tax positions and does not expect any material changes in uncertain tax benefits during the next 12 months. The Company recognizes interest and penalties related to income tax matters in income tax expense. The Company is subject to U.S. federal income tax as well as income tax in various states. The Company is generally not subject to examination by taxing authorities for years prior to 2021.

The Company recognizes deferred tax assets to the extent that the Company believes that these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations.

 <br> Page 20

------

**11. &nbsp;&nbsp;&nbsp;&nbsp;Earnings Per Share**

Income per common share is calculated using earnings for the year divided by the weighted average number of shares outstanding during the year. Using the treasury stock method, diluted income per share amounts are calculated giving effect to the potential dilution that would occur if securities or other contracts to issue common shares were exercised or converted to common shares by assuming the proceeds received from the exercise of stock options and the vesting of RSUs are used to purchase common shares at the prevailing market rate.

The following reflects the earnings and share data used in the basic and diluted earnings per share computations:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended June 30,** | **Three Months Ended June 30,** | **Six Months Ended June 30,** | **Six Months Ended June 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| **Numerator - basic and diluted:** |  |  |  |  |
| Net income attributable to Viemed Healthcare, Inc. | $3157 | $1468 | $5782 | $3071 |
| **Denominator:** |  |  |  |  |
| Basic weighted-average number of common shares | 39515247 | 38822980 | 39471244 | 38558479 |
| Diluted weighted-average number of shares | 41083760 | 40553449 | 41393523 | 40313042 |
| Basic earnings per share | $0.08 | $0.04 | $0.15 | $0.08 |
| Diluted earnings per share | $0.08 | $0.04 | $0.14 | $0.08 |
| **Denominator calculation from basic to diluted:** |  |  |  |  |
| Basic weighted-average number of common shares | 39515247 | 38822980 | 39471244 | 38558479 |
| Stock options and other dilutive securities | 1568513 | 1730469 | 1922279 | 1754563 |
| Diluted weighted-average number of shares | 41083760 | 40553449 | 41393523 | 40313042 |

---

Anti-dilutive shares excluded from the calculation consisted of dilutive employee stock options and RSUs that were de minimis in all periods presented.

**12. &nbsp;&nbsp;&nbsp;&nbsp;Subsequent Events**

On July 1, 2025, the Company completed the acquisition of Lehan's Medical Equipment, a privately held provider of home medical equipment headquartered in DeKalb, Illinois. The acquisition consideration includes a base purchase price of $26 million, subject to customary adjustments, and estimated contingent consideration of approximately $2.2 million.

The transaction was funded using $9.0 million from the Company's 2022 Revolving Credit Facility, $9.0 million from the 2022 Term Loan Facility, and the remainder with cash on hand.

 <br> Page 21

------

**Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations**

*The following discussion and analysis of our financial condition and results of operations should be read in conjunction with, and is qualified entirely by, our condensed consolidated financial statements (including Notes to the Condensed Consolidated Financial Statements) and the other consolidated financial information under Item 1 of this Quarterly Report on Form 10-Q. Some of the information in this discussion and analysis includes forward-looking statements that involve risk and uncertainties. Actual results and timing of events could differ from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.*

**<u>Forward-Looking Statements</u>**

Certain statements and information in this Quarterly Report on Form 10-Q may constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 or "forward-looking information" as such term is defined in applicable Canadian securities legislation (collectively, "forward-looking statements"). Any statements other than statements of historical information, including those that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance, including the Company's expectations about its acquisition of Lehan's Medical Equipment, such as contingent payments and anticipated benefits, are not historical facts and may be forward-looking and may involve estimates, assumptions and uncertainties that could cause actual results or outcomes to differ materially from those expressed in the forward-looking statements. These forward-looking statements are made as of the date hereof. We undertake no obligation to publicly update or revise any forward-looking statements after the date they are made, whether as a result of new information, future events or otherwise, except as required by applicable law.

Forward-looking statements relate to future events or future performance and reflect the expectations or beliefs of management regarding future events, and include, but are not limited to, statements with respect to: operating results; profitability; financial condition and resources; anticipated needs for working capital; liquidity; capital resources; capital expenditures; milestones; licensing milestones; information with respect to future growth and growth strategies; anticipated trends in our industry; our future financing plans; timelines; currency fluctuations; government regulation; unanticipated expenses; commercial disputes or claims; limitations on insurance coverage or other reimbursement; and availability of cash flow to fund capital requirements. Often, but not always, forward-looking information can be identified by the use of words such as "plans", "expects", "is expected", "budget", "potential", "scheduled", "estimates", "forecasts", "intends", "anticipates", "believes", "projects", or the negatives thereof or variations of such words and phrases or statements that certain actions, events or results "will", "should", "may", "could", "would", "might" or "will be taken", "occur" or "be achieved" or the negative of these terms or comparable terminology.

Forward-looking statements are based on the reasonable assumptions, estimates, analysis and opinions of management made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances at the date that such statements are made, but which may prove to be incorrect. We believe that the assumptions and expectations reflected in such forward-looking statements are reasonable. We cannot assure you, however, that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.

By their nature, forward-looking statements involve numerous assumptions, inherent risks and uncertainties, both general and specific, including those identified under "Item 1A. Risk Factors" and elsewhere in this Quarterly Report on Form 10-Q and the other documents we file with the SEC, including under "Item 1A. Risk Factors" of our Annual Report on Form 10-K for the year ended December 31, 2024, and with the securities regulatory authorities in certain provinces of Canada, which contribute to the possibility that the predicted outcomes may not occur or may be delayed. The risks, uncertainties and other factors, many of which are beyond our control, that could influence actual results include, but are not limited to: the general business, market and economic conditions in the regions in which the we operate; significant capital requirements and operating risks that we may be subject to; our ability to implement business strategies and pursue business opportunities; volatility in the market price of our common shares; the state of the capital markets; the availability of funds and resources to pursue operations; inflation; reductions in reimbursement rates and audits of reimbursement claims by various governmental and private payor entities; dependence on few payors; possible new drug discoveries; dependence on key suppliers; granting of permits and licenses in a highly regulated business; competition; disruptions in or attacks (including cyber-attacks) on our information technology, internet, network access or other voice or data communications systems or services; the evolution of various types of fraud or other criminal behavior to which we are exposed; difficulty integrating newly acquired businesses; the impact of new and changes to, or application of, current laws and regulations; the overall difficult litigation and regulatory environment; increased competition; increased funding costs and market volatility due to market illiquidity and competition for funding; critical accounting estimates and changes to accounting standards, policies, and methods used by us; and the occurrence of natural and unnatural catastrophic events or health epidemics or concerns, and claims resulting from such events or concerns, as well as other general economic, market and business conditions; and other factors beyond our control.

 <br> Page 22

------

**<u>General Matters</u>**

In this Quarterly Report on Form 10-Q, unless the context otherwise requires, the terms the "Company," "we," "us" and "our" refer to Viemed Healthcare, Inc. and subsidiaries in which it has a controlling financial interest.

We were incorporated on December 14, 2016 pursuant to the *Business Corporations Act* (British Columbia). As of June 30, 2020, we determined that we no longer qualify as a "foreign private issuer," as defined in Rule 3b-4 of the Exchange Act, for the purposes of the informational requirements of the Exchange Act. As a result, effective January 1, 2021, we became subject to the proxy solicitation rules under Section 14 of the Exchange Act and Regulation FD, and our officers, directors, and principal shareholders became subject to the reporting and short-swing profit recovery provisions contained in Section 16 of the Exchange Act. We will continue to file annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K with the SEC and with the relevant Canadian securities regulatory authorities on the System for Electronic Document Analysis and Retrieval (SEDAR).

**<u>Overview</u>**

We provide an array of home medical equipment, services and supplies, specializing in post-acute respiratory care services in the United States. Our primary objective is to focus on the organic growth of the business and thereby solidify our position as one of the United States' largest providers of in-home therapy for patients suffering from respiratory diseases. Our respiratory care programs are designed specifically for payors to have the ability to treat patients in the home for less total cost and with a superior quality of care. Our services include respiratory disease management (through the rental of various HME devices), neuromuscular care, in-home sleep testing and sleep apnea treatment, oxygen therapy, the sale of associated supplies, and healthcare staffing services.

We derive the majority of our revenue through the rental of non-invasive and invasive ventilators which represented 53.6% and 55.4% of our revenue for the three months ended June 30, 2025 and 2024, respectively, and 54.0% and 56.5% for the six months ended June 30, 2025 and 2024, respectively. We combine the benefits of home ventilation support with licensed Respiratory Therapists ("RTs") to drive improved patient outcomes and reduce costly hospital readmissions.

We expect to grow through expansion of existing service areas as well as in new territories through a cost efficient launch that reduces location expenses. We currently serve patients in all 50 states. We anticipate expanding our workforce of RTs to support our growth and ensure our high service model is maintained in the home. As of June 30, 2025, we employed 414 licensed RTs, representing approximately 33% of our company-wide employee count. Beyond fulfilling our internal staffing needs, we also provide healthcare staffing and recruitment services, offering tailored workforce solutions to external healthcare institutions and partners seeking qualified clinical professionals.

By focusing overhead costs on personnel that service the patient rather than physical location costs, we anticipate that we will efficiently scale our business in territories that are currently not being effectively serviced.

The continued trend of servicing patients in the home rather than in hospitals is aligned with our business objective and we anticipate that this trend will continue to offer growth opportunities for us. We expect to continue to be a solution to the rising health costs in the United States by offering more cost effective, home based solutions while increasing the quality of life for patients fighting serious respiratory diseases.

 <br> Page 23

------

**<u>Trends Affecting our Business</u>**

Home medical equipment markets are witnessing sustained expansion, with a notable focus on the complex respiratory and Obstructive Sleep Apnea ("OSA") device segments. Analysts in the industry anticipate a consistent and robust growth trajectory, projecting Compound Annual Growth Rates ("CAGR") of approximately 6% for respiratory devices and 8% for OSA devices. This upward trend underscores the increasing demand for innovative solutions in respiratory care and sleep apnea management, highlighting the industry's responsiveness to evolving healthcare needs. As technological advancements and awareness drive the adoption of these specialized devices, we believe the HME markets, particularly in respiratory and OSA, are positioned for continuous expansion, offering promising opportunities for both providers and consumers alike.

The aging population remains a pivotal driver for the industry, as the elderly, constituting a substantial portion of HME patients, are expected to represent a higher percentage of the overall population. Projections from industry analysts indicate a consistent annual growth in the number of Medicare beneficiaries, contributing to ongoing patient volume growth. A significant contributing factor to the industry's growth is the rising incidence of chronic diseases. Factors such as increasing obesity rates, consequences of past smoking prevalence, under-diagnosis of certain health conditions, and higher diagnosis rates for chronic diseases collectively shape the industry. There is a notable shift towards home-based treatment for these conditions.

The industry is undergoing a transition to value-based healthcare, with both government and commercial payors increasingly adopting models that emphasize the transition of patients from acute care settings to home care. We believe HME providers are well-positioned to benefit from this industry shift. Advancements in technology and medical equipment have led to an increased prevalence of in-home treatments. The broader range of treatments administered in patient homes is expected to continue growing. Projections from industry analysts indicate that U.S. home healthcare spending will increase, reaching $250 billion by 2031, with a CAGR of approximately 7%.

Market consolidation is a notable trend favoring larger, financially stable players. The decline in the number of smaller regional players is attributed to the capital investment and scale required to compete effectively. This has led to a more consolidated and competitive landscape in the durable medical equipment ("DME") market.

Despite these positive trends, the industry faces challenges such as cost containment efforts of payors. The consolidation of managed care payors into larger purchasing groups has increased negotiating power, resulting in pricing pressure on HME providers. In addition to ongoing negotiations relating to contract management with third party payors to secure fair reimbursement, HME providers are engaging in value-based contracting, focusing on outcomes and patient satisfaction. These value-based contracts leverage data analytics to demonstrate the cost-effectiveness and quality of durable medical goods and provide evidence-based data to payors demonstrating the long-term benefits and cost savings associated with the use of certain medical goods.

Regulatory uncertainty remains a key risk. Future changes in federal spending priorities, program eligibility, and administrative policies may materially affect the HME industry. Notably, the recent finalization of the "One Big Beautiful Bill Act" (OBBBA) has introduced significant healthcare reforms that could impact reimbursement structures, coverage policies, and provider obligations. Additionally, the implementation of Pay-As-You-Go (PAYGO) budgeting rules may result in further adjustments to Medicare and Medicaid spending, potentially leading to additional cost containment measures or payment reductions that could affect HME providers. As the industry adjusts to these developments, providers must continue to monitor and adapt to the evolving regulatory environment.

In addition, ventilator coverage remains a key area of regulatory focus. Although ventilators have historically been included under the National Coverage Determination ("NCD") for the Durable Medical Equipment Reference List, which has been in effect since April 1, 2003, there is currently no dedicated coverage policy that specifically addresses ventilator use. On September 11, 2024, the CMS initiated a national coverage analysis (NCA) to evaluate the use of noninvasive positive pressure ventilation in the home for the treatment of chronic respiratory failure related to chronic obstructive pulmonary disease. CMS released a proposed decision memo on March 11, 2025, and issued the final NCD on June 9, 2025. We have actively participated in the NCD process through formal comments and ongoing engagement with CMS, the Department of Health and Human Services, and members of Congress. The final NCD establishes clear medical necessity criteria for ventilator use that are expected to impact patient access, reimbursement, and utilization of ventilator therapies. This development may have a material effect on our business.

**Impact of Inflation**

The Company faces current and potential future inflationary pressures driven by factors such as general cost increases, supply chain disruptions, and governmental policies. The manufacturing and distribution costs of Viemed's patient equipment are affected by rising material, labor, and transportation expenses, including fuel costs. Persistent inflation may impact overall demand, increase operating costs, and affect profit margins, potentially adversely affecting Viemed's business and financial performance.

 <br> Page 24

------

In its 2025 DMEPOS Fee Schedule, CMS announced the fee schedule adjustment based on the annual change to the Consumer Pricing Index for all urban areas. Items that were subject to the competitive bidding program in former competitive bidding areas will receive a 2.9% reimbursement rate increase. Items that were subject to the competitive bidding program in non-competitive bidding areas received a 3.0% reimbursement rate increase. Items not subject to the competitive bidding program received a 2.4% reimbursement rate increase.

As discussed in Part II, Item 1A of this Quarterly Report on Form 10-Q, we are exposed to risks related to our reliance on third-party suppliers, including those associated with evolving trade policies and tariff regimes. In early 2025, the U.S. government announced new tariffs on a broad range of imported goods from multiple countries, prompting reciprocal tariffs from affected trade partners. While medical equipment has traditionally been excluded from such tariffs, the expanded scope of recent trade measures and the possibility of further escalation create significant uncertainty around equipment pricing and supply availability. The timing, scope, and final implementation of these tariffs remain unpredictable. The Company is actively monitoring these developments and continuously assessing their potential operational and financial impacts.

Future volatility in general price inflation and its impact on material availability, shipping, warehousing, and operational overhead could further impact financial results. Viemed attempts to address these pressures through its inflation-linked reimbursement contracts, negotiation, leveraging its purchasing power and embracing technology, such as its proprietary clinical management platform.

 <br> Page 25

------

The below table highlights summary financial and operational metrics for the last eight quarters.

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| ***(Tabular amounts expressed in thousands of U.S. Dollars, except vent patients)*** | ***(Tabular amounts expressed in thousands of U.S. Dollars, except vent patients)*** | ***(Tabular amounts expressed in thousands of U.S. Dollars, except vent patients)*** | ***(Tabular amounts expressed in thousands of U.S. Dollars, except vent patients)*** | ***(Tabular amounts expressed in thousands of U.S. Dollars, except vent patients)*** | ***(Tabular amounts expressed in thousands of U.S. Dollars, except vent patients)*** | ***(Tabular amounts expressed in thousands of U.S. Dollars, except vent patients)*** | ***(Tabular amounts expressed in thousands of U.S. Dollars, except vent patients)*** | ***(Tabular amounts expressed in thousands of U.S. Dollars, except vent patients)*** |
| **For the quarter ended** | **June 30,<br>2025** | **March 31, 2025** | **December 31, 2024** | **September 30, 2024** | **June 30, 2024** | **March 31, 2024** | **December 31, 2023** | **September 30, 2023** |
| **Financial Information:** | **Financial Information:** | | | | | | | |
| Revenue | $63056 | $59129 | $60695 | $58004 | $54965 | $50593 | $50739 | $49402 |
| Gross Profit | $36731 | $33279 | $36138 | $34371 | $32892 | $29802 | $32111 | $30562 |
| Gross Profit % | 58% | 56% | 60% | 59% | 60% | 59% | 63% | 62% |
| Net Income attributable to Viemed Healthcare, Inc.  | $3157 | $2625 | $4316 | $3878 | $1468 | $1603 | $3477 | $2919 |
| Cash and Cash Equivalents (As of) | $20016 | $10160 | $17540 | $11347 | $8807 | $7309 | $12839 | $10078 |
| Total Assets (As of) | $184603 | $178079 | $177069 | $169526 | $163947 | $154875 | $154895 | $149400 |
| Adjusted EBITDA<sup>(1)</sup> | $14287 | $12765 | $14242 | $13954 | $12813 | $10098 | $12845 | $12081 |
| **Operational Information:** | **Operational Information:** |  |  |  |  |  |  |  |
| Vent Patients<sup>(2)</sup> | 12152 | 11809 | 11795 | 11374 | 10905 | 10450 | 10327 | 10244 |
| PAP Therapy Patients<sup>(3)</sup> | 26260 | 22899 | 21338 | 19478 | 17349 | 15726 | 14900 | 14788 |
| Sleep Resupply Patients<sup>(4)</sup> | 25246 | 22941 | 24478 | 22143 | 20185 | 18904 | 18902 | 18544 |

---

<sup>(1)</sup> Refer to "Non-GAAP Financial Measures" section below for definition of Adjusted EBITDA.

<sup>(2)</sup> Vent Patients represents the number of active ventilator patients on recurring billing service at the end of each calendar quarter.

<sup>(3)</sup> PAP Therapy Patients represents the number of distinct patients billed for PAP therapy services during each calendar quarter.

<sup>(4)</sup> Sleep Resupply Patients represents the number of distinct patients who received supplies through our sleep resupply program during each calendar quarter.

 <br> Page 26

------

**<u>Results of Operations</u>**

**<u>Comparison of the Three Months Ended June 30, 2025 and 2024:</u>**

The following table summarizes our results of operations for the three months ended June 30, 2025 and 2024:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended June 30,** | **Three Months Ended June 30,** | **Three Months Ended June 30,** | **Three Months Ended June 30,** | **Three Months Ended June 30,** | **Three Months Ended June 30,** |
| | **2025** | **% of Total Revenue** | **2024** | **% of Total Revenue** | **$ Change** | **% <br>Change** |
| **Revenue** | $**63056** | **100.0%** | $**54965** | **100.0%** | $**8091** | **14.7%** |
| Cost of revenue | 26325 | 41.7% | 22073 | 40.2% | 4252 | 19.3% |
| **Gross profit** | **36731** | **58.3%** | **32892** | **59.8%** | **3839** | **11.7%** |
| Selling, general and administrative | 28803 | 45.7% | 26503 | 48.2% | 2300 | 8.7% |
| Research and development | 847 | 1.3% | 758 | 1.4% | 89 | 11.7% |
| Stock-based compensation | 2341 | 3.7% | 1620 | 2.9% | 721 | 44.5% |
| Depreciation and amortization | 353 | 0.6% | 377 | 0.7% | (24) | (6.4)% |
| Gain on disposal of property and equipment | (636) | (1.0)% | (545) | (1.0)% | (91) | 16.7% |
| Other expense (income), net | (72) | (0.1)% | 563 | 1.0% | (635) | (112.8)% |
| **Income from operations** | **5095** | **8.1%** | **3616** | **6.6%** | **1479** | **40.9%** |
| **Non-operating income and expenses** |  |  |  |  |  |  |
| Loss on investments |  | —% | (1117) | (2.0)% | 1117 | (100.0)% |
| Interest expense, net | (132) | (0.2)% | (254) | (0.5)% | 122 | (48.0)% |
| **Net income before taxes** | **4963** | **7.9%** | **2245** | **4.1%** | **2718** | **121.1%** |
| Provision for income taxes | 1713 | 2.7% | 768 | 1.4% | 945 | 123.0% |
| **Net income** | **3250** | **5.2%** | **1477** | **2.7%** | **1773** | **120.0%** |
| Net income attributable to noncontrolling interest | 93 | 0.2% | 9 | —% | 84 | 933.3% |
| **Net income attributable to Viemed Healthcare, Inc.** | $**3157** | **5.0%** | $**1468** | **2.7%** | $**1689** | **115.1%** |

---

*Revenue*

The following table summarizes our revenue for the three months ended June 30, 2025 and 2024:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended June 30,** | **Three Months Ended June 30,** | **Three Months Ended June 30,** | **Three Months Ended June 30,** | **Three Months Ended June 30,** | **Three Months Ended June 30,** |
| | **2025** | **% of Total Revenue** | **2024** | **% of Total Revenue** | **$ Change** | **% <br>Change** |
| ***Revenue from rentals*** |  |  |  |  |  |  |
| Ventilator rentals, non-invasive and invasive | $33819 | 53.6% | $30445 | 55.4% | $3374 | 11.1% |
| Other home medical equipment rentals | 13823 | 21.9% | 12211 | 22.2% | 1612 | 13.2% |
| ***Revenue from sales and services*** |  |  |  |  |  |  |
| Equipment and supply sales | 9514 | 15.1% | 7378 | 13.4% | 2136 | 29.0% |
| Service revenues | 5900 | 9.4% | 4931 | 9.0% | 969 | 19.7% |
| **Total revenue** | $**63056** | **100.0%** | $**54965** | **100.0%** | $**8091** | **14.7%** |

---

For the three months ended June 30, 2025, revenue totaled $63.1 million, an increase of $8.1 million (or 14.7%) from the comparable period in 2024. The primary driver of this growth was our ventilator rental revenue, which increased by $3.4 million (or 11.1%) due to higher patient volumes associated with strong demand for ventilation services. Additionally, rental revenue from other home medical equipment increased by $1.6 million (or 13.2%) due to an expanding patient base, robust demand for Positive Airway Pressure (PAP) therapy, oxygen therapy, and percussion vest services. Equipment and supply sales grew by $2.1 million (or 29.0%) largely attributable to the success of our sleep resupply program. Furthermore, services revenue experienced an increase of $1.0 million (or 19.7%) primarily due to the growth of healthcare staffing offerings.

While ventilator rentals continue to make up the majority of our revenue, the growth of PAP and oxygen related sales, as well as our healthcare staffing offerings, is contributing to the diversity of our overall revenue mix. As we broaden our geographic footprint and deepen our presence in existing markets, we expect further growth in our ventilator patient base. Additionally, the continued expansion of existing home medical equipment offerings, together with the introduction of new and complementary products, is expected to serve as an additional driver of revenue growth in future periods.

 <br> Page 27

------

*Cost of revenue and gross profit*

Cost of revenue for the three months ended June 30, 2025 was $26.3 million, an increase of $4.3 million (or 19.3%) compared to the same period in 2024. This increase was primarily driven by higher patient volumes and the expansion of our service offerings, which contributed to overall revenue growth.

Gross profit margin declined modestly to 58.3% in the three months ended June 30, 2025, down from 59.8% in the prior-year comparable period. The decrease in gross margin was largely driven by changes in our revenue mix associated with the diversification of our products and services.

We expect that continued growth and scaling of our operations may lead to improved cost efficiency over time. However, the margin impact of an evolving revenue mix could partially offset these benefits. As a result, gross margins may fluctuate in future periods depending on the composition of revenue sources and the degree to which we are able to capture economies of scale.

*Selling, general and administrative expense*

Selling, general, and administrative expenses as a percentage of revenue improved to 45.7% for the three months ended June 30, 2025 compared to 48.2% for the three months ended June 30, 2024. Selling, general and administrative expenses totaled $28.8 million for the three months ended June 30, 2025, an increase of $2.3 million (or 8.7%) from the comparable period in 2024.

The improvement in selling, general, and administrative expenses as a percentage of revenue reflects the benefits of operating leverage and continued gains in operational efficiency. The overall increase in selling, general and administrative expense as compared to the prior period is primarily attributable to additional employee related expenses to accommodate the overall growth of the Company. Employee compensation expenses increased $1.8 million (or 9.9%) as a result of the increase in our employee headcount. We expect that selling, general and administrative expenses as a percentage of revenue will continue to improve through the end of 2025 supported by ongoing efficiency initiatives and disciplined cost management.

*Research and development*

For the three months ended June 30, 2025, research and development expense totaled $0.8 million, an increase of $0.1 million from the comparable period in 2024. As we continue to invest in research and development related projects to support our technology initiatives, we expect that the associated costs will remain consistent in 2025 relative to 2024.

*Stock-based compensation*

For the three months ended June 30, 2025, stock-based compensation totaled $2.3 million, an increase of 44.5% from the comparable period in 2024. The increase reflects our continued investment in employee retention and long-term incentive programs, including the broader integration of equity-based awards into our compensation structure.

As we expand our workforce and align employee incentives with long-term shareholder value, we expect stock-based compensation to remain a consistent component of our cost structure throughout the remainder of 2025.

*Gain on disposal of property and equipment* 

For the three months ended June 30, 2025, gain on disposal of property and equipment totaled $0.6 million compared to gain on disposal of property and equipment of $0.5 million for the three months ended June 30, 2024. In both periods, the gains were primarily attributable to proceeds from the sale of recalled ventilators back to the manufacturer.

As our participation in the ventilator buyback program has substantially concluded, we do not expect further material gains from these transactions in future periods.

*Other expense (income), net*

For the three months ended June 30, 2025, other income totaled $0.1 million, compared to other expense of $0.6 million for the three months ended June 30, 2024. Other expense during the prior period is primarily due to an impairment of a litigation receivable of $0.9 million determined to be unrealizable as a result of the counterparty's bankruptcy proceedings.

*Loss on investments*

The $1.1 million loss on investments in the prior year period ended June 30, 2024 primarily reflects a loss recognized on a debt investment during the period. No investment related loss was recorded in the current period.

 <br> Page 28

------

*Interest expense, net*

Net interest expense was not significant for the three months ended June 30, 2025 or the comparable period in 2024. However, we expect net interest expense to increase over the remainder of 2025 following the issuance of debt to finance the acquisition of Lehan's Medical Equipment.

*Provision for income taxes*

For the three months ended June 30, 2025, the provision for income taxes was a $1.7 million expense, compared to a $0.8 million expense during the 2024 period. Our annual estimated effective tax rate for 2025 is 31.7%.

*Net income*

For the three months ended June 30, 2025, net income was $3.3 million, an increase of $1.8 million (or 120.0%) from the comparable period in 2024. Net income as a percentage of revenue increased from 2.7% for the three months ended June 30, 2024 to 5.2% for the three months ended June 30, 2025.

 <br> Page 29

------

**<u>Comparison of the Six Months Ended June 30, 2025 and 2024:</u>**

The following table summarizes our results of operations for the six months ended June 30, 2025 and 2024:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Six Months Ended June 30,** | **Six Months Ended June 30,** | **Six Months Ended June 30,** | **Six Months Ended June 30,** | **Six Months Ended June 30,** | **Six Months Ended June 30,** |
| | **2025** | **% of Total Revenue** | **2024** | **% of Total Revenue** | **$ Change** | **% <br>Change** |
| **Revenue** | $**122185** | **100.0%** | $**105558** | **100.0%** | $**16627** | **15.8%** |
| Cost of revenue | 52175 | 42.7% | 42864 | 40.6% | 9311 | 21.7% |
| **Gross profit** | **70010** | **57.3%** | **62694** | **59.4%** | **7316** | **11.7%** |
| Selling, general and administrative | 57228 | 46.8% | 51317 | 48.6% | 5911 | 11.5% |
| Research and development | 1644 | 1.3% | 1508 | 1.4% | 136 | 9.0% |
| Stock-based compensation | 4652 | 3.8% | 3052 | 2.9% | 1600 | 52.4% |
| Depreciation and amortization | 701 | 0.7% | 792 | 0.8% | (91) | (11.5)% |
| Gain on disposal of property and equipment | (3004) | (2.5)% | (332) | (0.3)% | (2672) | 804.8% |
| Other expense (income), net | (147) | (0.1)% | 537 | 0.5% | (684) | (127.4)% |
| **Income from operations** | **8936** | **7.3%** | **5820** | **5.5%** | **3116** | **53.5%** |
| **Non-operating income and expenses** |  |  |  |  |  |  |
| Loss on investments |  | —% | (1050) | (1.0)% | 1050 | (100.0)% |
| Interest expense, net | (311) | (0.2)% | (404) | (0.4)% | 93 | (23.0)% |
| **Net income before taxes** | **8625** | **7.1%** | **4366** | **4.1%** | **4259** | **97.5%** |
| Provision for income taxes | 2665 | 2.2% | 1286 | 1.2% | 1379 | 107.2% |
| **Net income** | **5960** | **4.9%** | **3080** | **2.9%** | **2880** | **93.5%** |
| Net income attributable to noncontrolling interest | 178 | 0.2% | 9 | —% | 169 | 1877.8% |
| **Net income attributable to Viemed Healthcare, Inc.** | $**5782** | **4.7%** | $**3071** | **2.9%** | $**2711** | **88.3%** |

---

*Revenue*

The following table summarizes our revenue for the six months ended June 30, 2025 and 2024:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Six Months Ended June 30,** | **Six Months Ended June 30,** | **Six Months Ended June 30,** | **Six Months Ended June 30,** | **Six Months Ended June 30,** | **Six Months Ended June 30,** |
| | **2025** | **% of Total Revenue** | **2024** | **% of Total Revenue** | **$ Change** | **% <br>Change** |
| ***Revenue from rentals*** |  |  |  |  |  |  |
| Ventilator rentals, non-invasive and invasive | $65979 | 54.0% | $59632 | 56.5% | $6347 | 10.6% |
| Other home medical equipment rentals | 26798 | 21.9% | 23145 | 21.9% | 3653 | 15.8% |
| ***Revenue from sales and services*** |  |  |  |  |  |  |
| Equipment and supply sales | 17020 | 13.9% | 13516 | 12.8% | 3504 | 25.9% |
| Service revenues | 12388 | 10.2% | 9265 | 8.8% | 3123 | 33.7% |
| **Total revenue** | $**122185** | **100.0%** | $**105558** | **100.0%** | $**16627** | **15.8%** |

---

For the six months ended June 30, 2025, revenue totaled $122.2 million, an increase of $16.6 million (or 15.8%) from the comparable period in 2024. The primary driver of this growth was our ventilator rental revenue, which increased by $6.3 million (or 10.6%) due to higher patient volumes associated with strong demand for ventilation services. Additionally, rental revenue from other home medical equipment increased by $3.7 million (or 15.8%) due to an expanding patient base, robust demand for Positive Airway Pressure (PAP) therapy, oxygen therapy, and percussion vest services. Equipment and supply sales grew by $3.5 million (or 25.9%) largely attributable to the success of our sleep resupply program. Furthermore, services revenue experienced an increase of $3.1 million (or 33.7%), primarily due to the growth of healthcare staffing offerings.

While ventilator rentals continue to make up the majority of our revenue, the growth of PAP and oxygen related sales, as well as our healthcare staffing offerings, is contributing to the diversity of our overall revenue mix. As we broaden our geographic footprint and deepen our presence in existing markets, we expect further growth in our ventilator patient base. Additionally, the continued expansion of existing home medical equipment offerings, together with the introduction of new and complementary products, is expected to serve as an additional driver of revenue growth in future periods.

 <br> Page 30

------

*Cost of revenue and gross profit*

Cost of revenue for the six months ended June 30, 2025 was $52.2 million, an increase of $9.3 million (or 21.7%) compared to the same period in 2024. This increase was primarily driven by higher patient volumes and the expansion of our service offerings, which contributed to overall revenue growth.

Gross profit margin declined to 57.3% in the six months ended June 30, 2025, down from 59.4% in the prior-year comparable period. The decrease in gross margin was largely driven by changes in our revenue mix associated with the diversification of our products and services.

We expect that continued growth and scaling of our operations may lead to improved cost efficiency over time. However, the margin impact of an evolving revenue mix could partially offset these benefits. As a result, gross margins may fluctuate in future periods depending on the composition of revenue sources and the degree to which we are able to capture economies of scale.

*Selling, general and administrative expense*

Selling, general, and administrative expenses as a percentage of revenue improved to 46.8% for the six months ended June 30, 2025 compared to 48.6% for the six months ended June 30, 2024. Selling, general and administrative expenses totaled $57.2 million for the six months ended June 30, 2025, an increase of $5.9 million (or 11.5%) from the comparable period in 2024.

The improvement in selling, general, and administrative expenses as a percentage of revenue reflects the benefits of operating leverage and continued gains in operational efficiency. The overall increase in selling, general and administrative expense as compared to the prior period is primarily attributable to additional employee related expenses to accommodate the overall growth of the Company, including the acquisition of HomeMed on April 1, 2024. Our full time employee count increased from 1,121 on June 30, 2024 to 1,258 on June 30, 2025, an increase of 12.2%. Employee compensation expenses increased $4.1 million (or 11%) as a result of the increase in our employee headcount. We expect that selling, general and administrative expenses as a percentage of revenue will continue to improve through the end of 2025 supported by ongoing efficiency initiatives and disciplined cost management.

*Research and development*

For the six months ended June 30, 2025, research and development expense totaled $1.6 million, an increase of $0.1 million from the comparable period in 2024. As we continue to invest in research and development related projects to support our technology initiatives, we expect that the associated costs will remain consistent in 2025 relative to 2024.

*Stock-based compensation*

For the six months ended June 30, 2025, stock-based compensation totaled $4.7 million, an increase of 52.4% from the comparable period in 2024. The increase reflects our continued investment in employee retention and long-term incentive programs, including the broader integration of equity-based awards into our compensation structure.

As we expand our workforce and align employee incentives with long-term shareholder value, we expect stock-based compensation to remain a consistent component of our cost structure throughout the remainder of 2025.

*Gain on disposal of property and equipment*

For the six months ended June 30, 2025, gain on disposal of property and equipment totaled $3.0 million compared to gain on disposal of property and equipment of $0.3 million for the six months ended June 30, 2024. In both periods, the gains were primarily attributable to proceeds from the sale of recalled ventilators back to the manufacturer.

As our participation in the ventilator buyback program has substantially concluded, we do not expect further material gains from these transactions in future periods.

*Other expense (income), net*

For the six months ended June 30, 2025, other income totaled $0.1 million, compared to other expense of $0.5 million for the six months ended June 30, 2024. Other expense during the prior period is primarily due to an impairment of a litigation receivable of $0.9 million determined to be unrealizable as a result of the counterparty's bankruptcy proceedings.

*Loss on investments*

 <br> Page 31

------

The $1.1 million loss on investments in the prior year period ended June 30, 2024 primarily reflects a loss recognized on a debt investment during the period. No investment related loss was recorded in the current period.

*Interest expense, net*

Net interest expense was not significant for the six months ended June 30, 2025 or the comparable period in 2024. However, we expect net interest expense to increase over the remainder of 2025 following the issuance of debt to finance the acquisition of Lehan's Medical Equipment.

*Provision for income taxes*

For the six months ended June 30, 2025, the provision for income taxes was a $2.7 million expense, compared to a $1.3 million expense during the 2024 period. Our annual estimated effective tax rate for 2025 is 31.7%.

*Net income*

For the six months ended June 30, 2025, net income was $6.0 million, an increase of $2.9 million (or 93.5%) from the comparable period in 2024. Net income as a percentage of revenue increased from 2.9% for the six months ended June 30, 2024 to 4.9% for the six months ended June 30, 2025.

 <br> Page 32

------

**<u>Non-GAAP Financial Measures</u>**

The Company uses Adjusted EBITDA, which is a financial measure that is not prepared in accordance with generally accepted accounting principles in the United States ("GAAP"). Adjusted EBITDA should be considered in addition to, not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. Management believes Adjusted EBITDA provides helpful information with respect to the Company's operating performance as viewed by management, including a view of the Company's business that is not dependent on the impact of the Company's capitalization structure and items that are not part of the Company's day-to-day operations. Management uses Adjusted EBITDA (i) to compare the Company's operating performance on a consistent basis, (ii) to calculate incentive compensation for the Company's employees, (iii) for planning purposes, including the preparation of the Company's internal annual operating budget, and (iv) to evaluate the performance and effectiveness of the Company's operational strategies. Accordingly, management believes that Adjusted EBITDA provides useful information in understanding and evaluating the Company's operating performance in the same manner as management. It is not a measurement of our financial performance under GAAP and should not be considered as an alternative to revenue or net income, as applicable, or any other performance measures derived in accordance with GAAP or as an alternative to cash flows from operating activities as a measure of the Company's liquidity. Adjusted EBITDA has limitations as an analytical tool and should not be considered in isolation or as a substitute for analysis of our operating results as reported under GAAP. Adjusted EBITDA does not reflect the impact of certain cash charges resulting from matters we consider not to be indicative of ongoing operations; and other companies in our industry may calculate Adjusted EBITDA differently than we do, limiting its usefulness as a comparative measure. In calculating Adjusted EBITDA, certain items (mostly non-cash) are excluded from net income attributable to Viemed Healthcare, Inc. including depreciation and amortization of capitalized assets, net interest expense, stock based compensation, transaction costs, impairment of assets, and taxes.

The following table is a reconciliation of net income attributable to Viemed Healthcare, Inc., the most directly comparable GAAP measure, to Adjusted EBITDA, on a historical basis for the periods indicated:

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **For the quarter ended** | **June 30, 2025** | **March 31, 2025** | **December 31, 2024** | **September 30, 2024** | **June 30, 2024** | **March 31, 2024** | **December 31, 2023** | **September 30, 2023** |
| **Net income attributable to Viemed Healthcare, Inc.** | $3157 | $2625 | $4316 | $3878 | $1468 | $1603 | $3477 | $2919 |
| Add back: |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;Depreciation & amortization | 6891 | 6613 | 6366 | 6408 | 6309 | 6285 | 5918 | 5975 |
| &nbsp;&nbsp;Interest expense, net | 132 | 179 | 147 | 225 | 254 | 150 | 256 | 237 |
| &nbsp;&nbsp;Stock-based compensation<sup>(a)</sup> | 2341 | 2311 | 1521 | 1712 | 1620 | 1432 | 1534 | 1453 |
| &nbsp;&nbsp;Transaction costs<sup>(b)</sup> | 53 | 85 | 11 | 12 | 221 | 110 | 61 | 177 |
| &nbsp;&nbsp;Impairment of assets<sup>(c)</sup> |  |  |  | 125 | 2173 |  |  |  |
| &nbsp;&nbsp;Income tax expense | 1713 | 952 | 1881 | 1594 | 768 | 518 | 1599 | 1320 |
| **Adjusted EBITDA** | $**14287** | $**12765** | $**14242** | $**13954** | $**12813** | $**10098** | $**12845** | $**12081** |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Represents non-cash, equity-based compensation expense associated with option and RSU awards.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Represents transaction costs and expenses related to acquisition and integration efforts associated with recently announced or completed acquisitions.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Represents impairments of the fair value of investment and litigation-related assets.

 <br> Page 33

------

**<u>Liquidity and Capital Resources</u>**

Cash and cash equivalents at June 30, 2025 was $20.0 million, compared to $17.5 million at December 31, 2024. Typically, our principal source of liquidity is the collection of our patient accounts receivable. In addition to our collection of patient accounts receivable, from time to time, we can and do obtain additional sources of liquidity by the incurrence of additional indebtedness. Based on our current plan of operations, we believe cash and cash equivalents, when combined with expected cash flows from operations and amounts available under our 2022 Senior Credit Facilities will be sufficient to fund our growth strategy and to meet our anticipated operating expenses, capital expenditures, and debt service obligations for at least the next 12 months from the date of this filing. The Company has also historically utilized short term financing arrangements with suppliers that could be extended over a longer term if there was a need for additional liquidity.

***Cash Flows***

The following table summarizes our cash flows for the periods indicated:

---

| | | |
|:---|:---|:---|
| | **Six Months Ended June 30,** | **Six Months Ended June 30,** |
| | **2025** | **2024** |
| Net Cash provided by (used in): |  |  |
| &nbsp;&nbsp;&nbsp;Operating activities | $15108 | $11357 |
| &nbsp;&nbsp;&nbsp;Investing activities | (10257) | (16532) |
| &nbsp;&nbsp;&nbsp;Financing activities | (2375) | 1143 |
| **Net increase (decrease) in cash and cash equivalents** | $**2476** | $**(4032)** |

---

*Net Cash Provided by Operating Activities*

Net cash provided by operating activities during the six months ended June 30, 2025 was $15.1 million, resulting from net income of $6.0 million, increased by net income adjustments of $13.3 million and offset by an increase in non-cash working capital of $4.1 million. The net income adjustments primarily consisted of $13.5 million of depreciation and amortization and $4.7 million of stock-based compensation, partially offset by a $3.0 million gain on disposal of property and equipment. The primary changes in non-cash working capital were an increase in net accounts receivable of $1.6 million, a decrease in accrued liabilities of $2.0 million, and a decrease in income tax payable of $2.4 million, partially offset by an increase in trade payables of $1.6 million.

Net cash provided by operating activities during the six months ended June 30, 2024 was $11.4 million, resulting from net income of $3.1 million, increased by net income adjustments of $16.5 million and offset by an increase in non-cash working capital of $8.2 million. The net income adjustments primarily consisted of $12.6 million of depreciation and amortization, $3.1 million of stock-based compensation, and a net loss from debt investment of $1.2 million. The primary changes in non-cash working capital were an increase in net accounts receivable of $8.2 million and a net change in income tax receivable of $2.6 million, partially offset by an increase in trade payables of $1.1 million.

*Net Cash Used in Investing Activities*

Net cash used in investing activities during the six months ended June 30, 2025 was $10.3 million, consisting of $23.6 million of purchases of property and equipment, partially offset by $13.4 million of sales proceeds from the disposal of property and equipment. Net cash used for capital expenditures represents a decrease of $3.3 million, or 24.2%, year over year. Purchases of property and equipment were primarily related to medical equipment rented to our patients.

Net cash used in investing activities during the six months ended June 30, 2024 was $16.5 million, consisting of $14.9 million of purchases of property and equipment, partially offset by $1.4 million of sales proceeds from the disposal of property and equipment. Purchases of property and equipment were primarily related to medical equipment rented to our patients. Net cash used in investing activities also included $3.0 million of net cash paid for the acquisition of HomeMed.

*Net Cash Provided by (Used in) Financing Activities*

Net cash used in financing activities during the six months ended June 30, 2025 was $2.4 million, consisting of $1.7 million of cash paid for common shares repurchased and cancelled pursuant to the 2025 Share Repurchase Program, $0.2 million in principal payments under the 2022 Senior Credit Facilities (as defined below), and $1.6 million for common shares repurchased and cancelled to satisfy employee income tax withholding associated with RSUs vested during the period, partially offset by $1.4 million of proceeds from the exercise of stock options.

 <br> Page 34

------

Net cash provided by financing activities during the six months ended June 30, 2024 was $1.1 million. For the six months ended June 30, 2024, proceeds from the 2022 Revolving Credit Facility (as defined below) were $3.0 million, which was used to fund the HomeMed acquisition. Principal payments on the 2022 Term Loan Facility (as defined below) were $0.1 million. Additionally, principal payments on acquired loans were $0.7 million during the six months ended June 30, 2024. The Company acquired and cancelled 129,983 common shares at a cost of $1.0 million to satisfy employee income tax withholding associated with RSUs vested during the period while proceeds from the exercise of options during the six months ended June 30, 2024 were $0.3 million.

***Senior Credit Facilities***

On November 29, 2022, the Company refinanced its existing borrowings under the prior Commercial Business Loan Agreement with Hancock Whitney Bank and entered into a new credit agreement (the "2022 Senior Credit Facilities") with the lenders from time to time party thereto, and Regions Bank, as administrative agent and collateral agent, that provides for an up to $30.0 million revolving credit facility (the "2022 Revolving Credit Facility") and an up to $30.0 million delayed draw term loan facility (the "2022 Term Loan Facility"), both maturing in November 2027. On May 28, 2024, the Company entered into a First Amendment to the 2022 Senior Credit Facilities that (a) extended the delayed draw term loan commitment expiration date to November 29, 2025, from its initial expiration date of May 29, 2024, and (b) provided for other technical amendments. On June 6, 2025, the Company entered into a Second Amendment to the 2022 Senior Credit Facilities that (a) increased the permitted amount of restricted payments that may be made by the Company and its subsidiaries subject to specified conditions, and (b) made other conforming and administrative changes.

The proceeds of the 2022 Revolving Credit Facility may be used to refinance existing indebtedness, for working capital purposes, capital expenditures and other general corporate purposes (including permitted acquisitions), and to pay transaction fees, costs and expenses related to the 2022 Senior Credit Facilities. The proceeds of the 2022 Term Loan Facility and any additional term loans established in accordance with the 2022 Senior Credit Facilities may be used to finance permitted acquisitions and to pay transaction fees, costs and expenses related to such acquisitions. Outstanding borrowings under the 2022 Term Loan Facility were $4.4 million as of June 30, 2025. There were no outstanding borrowings under the 2022 Revolving Credit Facility as of June 30, 2025.

The interest rates per annum applicable to the 2022 Senior Credit Facilities are Term SOFR plus an applicable margin, which ranges from 2.625% to 3.375%, or, at the option of the Company, a Base Rate (as defined in the 2022 Senior Credit Facilities) plus an applicable margin, which ranges from 1.625% to 2.375%.

The 2022 Senior Credit Facilities require the Company to comply with certain affirmative, as well as certain negative covenants that, among other things, will restrict, subject to certain exceptions, the ability of the Company to incur indebtedness, grant liens, make investments, engage in acquisitions, mergers or consolidations and pay dividends and other restricted payments. The 2022 Senior Credit Facilities also include certain financial covenants, which generally include, but are not limited to the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Consolidated Total Leverage Ratio (defined generally as total indebtedness to adjusted EBITDA) of not greater than (i) for any fiscal quarter ending during the period from the closing date to and including December 31, 2024, 2.75 to 1.0 and (ii) for any fiscal quarter ending on and after March 31, 2025, 2.50 to 1.0, subject to certain adjustments following a material acquisition.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Consolidated Fixed Charge Coverage Ratio (defined generally as (a) adjusted EBITDA minus capital expenditures minus cash taxes to (b) the sum of scheduled principal payments plus cash interest expense plus restricted payments) of not less than 1.25:1.0.

The Company was in compliance with all covenants under the 2022 Senior Credit Facilities in effect at June 30, 2025.

 <br> Page 35

------

**Use of Funds**

Our principal uses of cash are funding the purchase of rental assets and other capital purchases, the repayment of debt, funding of acquisitions, operations, and other working capital requirements. Our contractual obligations primarily relate to the repayment of existing debt and contractual obligations for operating and finance leases. The following table presents our material contractual obligations and commitments to make future payments as of June 30, 2025:

---

| | | |
|:---|:---|:---|
| | **Within 12 Months** | **Beyond 12 Months** |
| Debt Obligations, including interest | $1153 | $4369 |
| Lease Obligations | 1081 | 1849 |
| **Total** | $2234 | $6218 |

---

Except for the funding of potential acquisitions and investments, we anticipate that our operating cash flows will satisfy our material cash requirements for the 12 months after June 30, 2025. In addition to our operating cash flows, we may need to raise additional funds to support our contractual obligations and investing activities beyond such 12 month period, and such funding may not be available to us on acceptable terms, or at all. If we are unable to raise additional funds when needed, our operations and ability to execute our business strategy could be adversely affected. We may seek to raise additional funds through equity, equity-linked or debt financings. If we raise additional funds through the incurrence of indebtedness, such indebtedness would have rights that are senior to holders of our equity securities and could contain covenants that restrict our operations. Any additional equity financing may be dilutive to our stockholders.

*Leases*

Leases under which we assume substantially all the risks and rewards of ownership are classified as finance leases. Upon initial recognition, the leased asset is measured at an amount equal to the lesser of its fair value and the present value of the minimum lease payments. Subsequent to initial recognition, the asset is accounted for in accordance with the accounting policy applicable to the asset. The associated lease liability is drawn down over the life of the lease by allocating a portion of each lease payment to the liability with the remainder being recognized as finance charges. Leases that do not transfer the risks and rewards of ownership to the Company are treated as operating leases and are expensed as incurred.

*Retirement Plan*

The Company maintains a 401(k) retirement plan for employees to which eligible employees can contribute a percentage of their pre-tax compensation. Matching employer contributions to the 401(k) plan totaled $379,000 and $338,000 for the three months ended June 30, 2025 and 2024, respectively, and $945,000 and $873,000 for the six months ended June 30, 2025 and 2024, respectively.

**Off Balance Sheet Arrangements**

The Company has no material undisclosed off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on its results of operations or financial condition.

 <br> Page 36

------

**<u>Accounting and Disclosure Matters</u>**

**Critical Accounting Estimates**

We are required to disclose "critical accounting estimates" which are estimates made in accordance with generally accepted accounting principles that involve a significant level of estimation uncertainty and that have had or are reasonably likely to have a material impact on our financial condition or results of operations.

We follow financial accounting and reporting policies that are in accordance with accounting principles generally accepted in the United States. The more significant of these policies are summarized in Note 2 to our consolidated financial statements included in Part II, Item 8 of the Company's Annual Report on Form 10-K for the year ended December 31, 2024. Not all significant accounting policies require management to make difficult, subjective or complex judgments. However, the policy noted below could be deemed to meet the SEC's definition of a critical accounting estimate.

***Accounts Receivable***

Accounts receivable are recorded based upon contractually agreed-upon rates, reduced by estimated adjustments for variable consideration for implicit price concessions related to sales revenues and estimated probable losses related to rental revenues. Due to the nature of the industry and the reimbursement environment in which we operate, certain estimates are required in order to record revenues and accounts receivable net of these adjustments. Management's evaluation takes into consideration such factors as historical realization data, including current and historical cash collections, accounts receivable aging trends, other operating trends and relevant business conditions.

Inherent in these estimates is the risk that they may have to be revised or updated as additional information becomes available. It is possible that management's estimates could change, which could have an impact on operations and cash flows. Specifically, the complexity of many third-party billing arrangements, patient qualification for medical necessity of equipment and the uncertainty of reimbursement amounts for certain services from certain payors may result in adjustments to amounts originally recorded. If the payment amount received differs from the estimated amount, an adjustment is made in the period that these payment differences are determined.

**Recently Issued Accounting Pronouncements**

See Note 2 – Summary of Significant Accounting Policies of our Condensed Consolidated Financial Statements for a description of recently issued accounting pronouncements, including the expected dates of adoption and estimated effects on our results of operations, financial positions and cash flows.

 <br> Page 37

------

**Item 3. Quantitative and Qualitative Disclosures About Market Risk**

Our exposure to market risk primarily relates to fluctuations in interest rates from borrowings under the 2022 Senior Credit Facilities. The interest rates per annum applicable to the 2022 Senior Credit Facilities are Term SOFR plus an applicable margin, which ranges from 2.625% to 3.375%, or, at the option of the Company, a Base Rate (as defined in the 2022 Senior Credit Facilities) plus an applicable margin, which ranges from 1.625% to 2.375%. Outstanding borrowings subject to interest rate fluctuations under the 2022 Term Loan Facility were $4.4 million as of June 30, 2025. There were no outstanding borrowings under the 2022 Revolving Credit Facility as of June 30, 2025. Based on our outstanding borrowings, an immediate 100 basis point change in interest rates would not have a material effect on our net income.

**Item 4. Controls and Procedures**

**Evaluation of Disclosure Controls and Procedures**

As of the end of the period covered by this report, the Company's management, including its Chief Executive Officer and Chief Financial Officer, completed an evaluation of the effectiveness of the Company's disclosure controls and procedures pursuant to Rule 13a-15 of the Exchange Act. Based on that evaluation, the Chief Executive Officer and Chief Financial Officer concluded:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;i.that the Company's disclosure controls and procedures are designed to ensure (a) that information required to be disclosed by the Company in the reports it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC's rules and forms, and (b) that such information is accumulated and communicated to the Company's management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ii.that the Company's disclosure controls and procedures are effective.

Notwithstanding the foregoing, there can be no assurance that the Company's disclosures controls and procedures will detect or uncover all failures of persons within the Company and its consolidated subsidiaries to disclose material information otherwise required to be set forth in the Company's periodic reports. There are inherent limitations to the effectiveness of any system of disclosure controls and procedures, including the possibility of human error and the circumvention or overriding of the controls and procedures.

**Changes in Internal Control Over Financial Reporting**

There have been no changes in the Company's internal control over financial reporting during the three months ended June 30, 2025 that have materially affected, or that are reasonably likely to materially affect, the Company's internal control over financial reporting.

 <br> Page 38

------

**PART II - OTHER INFORMATION**

**Item 1. Legal Proceedings**

From time to time, we may be subject to various ongoing or threatened legal actions and other proceedings, including those that arise in the ordinary course of business, which may include employment matters, breach of contract disputes, as well as governmental and regulatory matters. Please read Note 9—Commitments and Contingencies to our condensed consolidated financial statements included in Part I, Item 1, of this Quarterly Report on Form 10-Q for more information. Such matters are subject to many uncertainties and to outcomes that are not predictable with assurance and that may not be known for extended periods of time.

**Item 1A. Risk Factors**

In addition to the other information set forth in this Quarterly Report on Form 10-Q, you should carefully consider the factors discussed in "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC on March 10, 2025, which could materially affect our business, financial condition or future results. Except as set forth below, there have been no material changes in our risk factors from those disclosed in that Annual Report.

***A reduction or elimination of coverage or reimbursement of our products by third-party payors, including Medicare, in the future could adversely affect our business and results of operations.***

A substantial portion of our revenues are derived from reimbursement by Medicare and other third-party payors for our ventilator products and services. Currently, ventilators are covered under the National Coverage Determination ("NCD") for the DME Reference List, effective since April 1, 2003, for the treatment of neuromuscular diseases, thoracic restrictive diseases, and chronic respiratory failure resulting from chronic obstructive pulmonary disease ("COPD"). While the DME Reference List has been updated, no standalone NCD has been issued for ventilators.

On June 9, 2025, CMS finalized a new NCD establishing clear medical necessity criteria for noninvasive positive pressure ventilation ("NIPPV") in the home for treatment of chronic respiratory failure related to COPD. We actively participated in the national coverage analysis process, including submission of formal comments and ongoing engagement with CMS, the Department of Health and Human Services, and members of Congress.

The final NCD may significantly affect patient access, reimbursement, and utilization of ventilator therapies. Because Medicare coverage policies often influence commercial payors, including Medicare Advantage plans, changes to Medicare policy may have broader implications across our payer base. Any reduction or elimination of coverage or reimbursement by Medicare or other third-party payors, or an inability to maintain or expand coverage with additional commercial payors, could materially and adversely impact our business, financial condition, and results of operations.

***Adverse global macroeconomic conditions, including supply chain disruptions, tariffs, and fluctuations in foreign currency exchange rates, could negatively impact our operations, costs, and profitability.***

Our business may be affected by a range of global macroeconomic conditions, including newly imposed tariffs, disruptions to the supply chain, and fluctuations in foreign currency exchange rates. While nearly all of our revenues are generated within the United States and denominated in U.S. dollars, we rely on both domestic and international suppliers for the medical equipment and supplies we rent and sell to patients. As a result, our cost structure and operational efficiency are subject to global market dynamics that may influence the availability and pricing of key products.

In early 2025, the U.S. government announced new tariffs on a broad range of imported goods from multiple countries, prompting reciprocal tariffs from affected trade partners. While medical equipment has traditionally been excluded from such tariffs, the expanded scope of recent trade measures and the possibility of further escalation create significant uncertainty around equipment pricing and supply availability. The timing, scope, and final implementation of these tariffs remain unpredictable. The Company is actively monitoring these developments and continuously assessing their potential operational and financial impacts.

Additionally, global supply chain constraints continue to pose risks to our ability to acquire essential equipment and components in a timely and efficient manner. Factors such as raw material shortages, longer lead times from suppliers, and increased transportation expenses may limit our responsiveness to patient needs and may affect our ability to scale the business effectively.

Although our operations are primarily domestic, we are indirectly exposed to foreign currency exchange rate fluctuations through our international sourcing activities. Changes in the value of the U.S. dollar relative to other currencies, including the Canadian dollar and Chinese yuan, may impact the prices we pay to suppliers, which could increase our cost of goods sold and reduce our gross margins.

 <br> Page 39

------

If these macroeconomic pressures persist or worsen, our ability to manage supply continuity, control costs, and meet patient demand could be adversely affected. As a result, our financial condition, operating results, and long-term strategic objectives may be negatively impacted.

***We cannot guarantee that we will repurchase our common shares pursuant to our share repurchase program or that our share repurchase program will enhance long-term shareholder value. Share repurchases could also increase the volatility of the price of our common shares and could diminish our cash reserves.***

On June 6, 2025, the Company's Board of Directors authorized and approved a share repurchase program, effective through June 2026. Under the terms of the program, we may repurchase up to 1,976,441 of our common shares from time to time through open market purchases, block purchases or otherwise in accordance with applicable securities laws, including Rule 10b-18 of the Exchange Act. The timing and amount of repurchases of our common shares, if any, will depend upon several factors, such as the market price of the common shares, corporate requirements, general market economic conditions and applicable legal requirements. The Company is not obligated to repurchase any specific number or amount of common shares pursuant to the program, and it may modify, suspend or discontinue the program at any time. Repurchases of our common shares pursuant to the program could affect our share price and increase its volatility. The existence of the program could cause our share price to be higher than it would be in the absence of such a program and, if shares are repurchased in the program, it will reduce the market liquidity for our common shares. Additionally, the program could diminish our cash reserves, which may impact our ability to finance future growth and to pursue possible future strategic opportunities. There can be no assurance that any share repurchases will enhance long-term shareholder value, and the market price of our common shares may decline below the levels at which we repurchased common shares.

**Item 2. Unregistered Sales of Equity Securities and Use of Proceeds**

**Unregistered Sales of Equity Securities**

None.

**Company Repurchases of Equity Securities**

The following table sets forth certain information with respect to repurchases of our common shares during the three months ended June 30, 2025:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Period** | **Total number of shares (or units) purchased** <sup>(1)</sup> | **Average price paid per share** <sup>(2)</sup> | **Total number of shares purchased as part of publicly announced plans or programs** <sup>(3)</sup> | **Maximum number of shares that may yet be purchased under the plans or programs** |
| Apr 1- Apr 30, 2025 |  | $— |  |  |
| May 1- May 31, 2025 | 6647 | $7.07 |  |  |
| Jun 1- Jun 30, 2025 | 270061 | $6.79 | 270061 | 1706380 |
| **Total** | 276708 | $6.79 | 270061 | 1706380 |

---

<sup>(1)</sup> This amount includes 6,647 common shares acquired at a cost of $47,000 to satisfy employee income tax withholding associated with RSUs vesting.

<sup>(2)</sup> Average price paid per share includes broker commissions.

<sup>(3)</sup> On June 6, 2025, the Company's Board of Directors authorized and approved a share repurchase program. Under the terms of the 2025 Share Repurchase Program, the Company may repurchase up to 1,976,441 of its common shares from time to time through open market purchases, block purchases or otherwise in accordance with applicable securities laws, including Rule 10b-18 of the Exchange Act. The 2025 Share Repurchase Program is set to expire in June 2026, unless earlier suspended or terminated.

**Dividends**

We have not declared or paid any cash or stock dividends on our common shares since our inception. Any future determination as to the declaration and payment of cash dividends will be at the discretion of the Board and will depend on then-existing conditions, including our financial condition, results of operations, contractual restrictions, capital requirements, business prospects, and other factors that the Board considers relevant. Our subsidiaries are restricted from making distributions or dividend payments to us by the 2022 Senior Credit Facilities (as defined above), subject to certain exceptions. See Note 6 to the Financial Statements, included in Part I, Item 1, of this Quarterly Report on Form 10-Q for further information.

 <br> Page 40

------

**Item 3. Defaults Upon Senior Securities**

None.

**Item 4. Mine Safety Disclosures**

Not applicable.

**Item 5. Other Information**

*Rule 10b5-1 and Non-Rule 10b5-1 Trading Arrangements*

During the fiscal quarter ended June 30, 2025, no director or officer (as defined in Rule 16a-1(f) of the Securities Exchange Act of 1934) of the Company adopted or terminated any Rule 10b5-1 trading arrangements or non-Rule 105-1 trading arrangements as each term is defined in Item 408(a) of Regulation S-K.

 <br> Page 41

------

**Item 6. Exhibits**

The exhibits filed as part of this Quarterly Report on Form 10-Q are set forth on the Exhibit Index below.

---

| | |
|:---|:---|
| **Exhibit Number** | **Exhibit Title** |
| #2.1 | <u>[Stock Purchase Agreement dated April 18, 2023 by and among Viemed, Inc., the Stockholders and Home Medical Products, Inc. Incorporated by reference to Exhibit 2.1 to the Company's Current Report on Form 8-K filed on April 19, 2023.](https://www.sec.gov/Archives/edgar/data/1729149/000172914923000050/ex2141823stockpurchaseagre.htm)</u> |
| 3.1 | <u>[Notice of Articles of Business Corporation Act of Viemed Healthcare, Inc. Incorporated by reference to Exhibit 3.1 to the Company's Registration Statement on Form 10 filed on July 10, 2019.](https://www.sec.gov/Archives/edgar/data/1729149/000114036119012755/ex3_1.htm)</u> |
| 3.2 | <u>[Amended and Restated Business Corporation Act Articles of Viemed Healthcare, Inc. Incorporated by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K filed on June 10, 2021.](https://www.sec.gov/Archives/edgar/data/1729149/000172914921000101/exhibit31.htm)</u> |
| 10.1 | &nbsp;&nbsp;&nbsp;&nbsp;<br><u>[Amendment to the 2024 Long Term Incentive Plan, effective June 5, 2025. Incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed on June 5, 2025.](https://www.sec.gov/Archives/edgar/data/1729149/000172914925000098/firstamendmentviemedhealth.htm)</u> |
| 10.2 | <u>[Second Amendment to Credit Agreement dated November 29, 2022, among Viemed Inc. as borrower, certain subsidiaries of Viemed, Inc., as guarantors, the lenders from time to time party thereto, and Regions Bank, as administrative agent and collateral agent, effective June 6, 2025. Incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed on June 9, 2025.](https://www.sec.gov/Archives/edgar/data/1729149/000172914925000101/a1012ndamendmentto2022cred.htm)</u> |
| \*31.1 | <u>[Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](q22025exhibit311.htm)</u> |
| \*31.2 | <u>[Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](q22025exhibit312.htm)</u> |
| \*\*32.1 | <u>[Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350.](q22025exhibit321.htm)</u> |
| \*\*32.2 | <u>[Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350.](q22025exhibit322.htm)</u> |
| \*101.INS | Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. |
| \*101.SCH | Inline XBRL Taxonomy Extension Schema Document. |
| \*101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document. |
| \*101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document. |
| \*101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document. |
| \*101.DEF | Inline XBRL Taxonomy Extension Definition Document. |
| \*104 | Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101) |
| \* Filed herewith. | \* Filed herewith. |
| \*\* Furnished in accordance with Item 601(b)(32)(ii) of Regulation S-K. | \*\* Furnished in accordance with Item 601(b)(32)(ii) of Regulation S-K. |
| # Schedules and similar attachments have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company will furnish supplementally a copy of any omitted schedule or similar attachment to the Securities and Exchange Commission upon request. | # Schedules and similar attachments have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company will furnish supplementally a copy of any omitted schedule or similar attachment to the Securities and Exchange Commission upon request. |

---

 <br> Page 42

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange of Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | |
|:---|:---|
| VIEMED HEALTHCARE, INC. | VIEMED HEALTHCARE, INC. |
| (Registrant) | (Registrant) |
| By: | /s/ Casey Hoyt |
|  | Casey Hoyt |
|  | Chief Executive Officer |
| By: | /s/ Trae Fitzgerald |
|  | Trae Fitzgerald |
|  | Chief Financial Officer |

---

Date: August 6, 2025

 <br> Page 43

## Exhibit 31.1

**Certification of Principal Executive Officer Pursuant to Exchange Act Rule 13a-14(a)/15d-14(a) as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002**

I, Casey Hoyt, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Viemed Healthcare, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 6, 2025

---

| |
|:---|
| /s/ Casey Hoyt |
| Casey Hoyt<br>Chief Executive Officer |

---

## Exhibit 31.2

**Certification of Principal Financial Officer Pursuant to Exchange Act Rule 13a-14(a)/15d-14(a) as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002**

I, Trae Fitzgerald, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Viemed Healthcare, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 6, 2025

---

| |
|:---|
| /s/ Trae Fitzgerald |
| Trae Fitzgerald<br>Chief Financial Officer |

---

## Exhibit 32.1

**Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002**

Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, I, Casey Hoyt, the Chief Executive Officer of Viemed Healthcare, Inc. (the "**Company**"), hereby certify, that, to my knowledge:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.The Quarterly Report on Form 10-Q for the period ended June 30, 2025 (the "**Report**") of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;&nbsp;&nbsp;&nbsp;The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 6, 2025

---

| |
|:---|
| /s/ Casey Hoyt |
| Casey Hoyt<br>Chief Executive Officer |

---

## Exhibit 32.2

**Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002**

Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, I, Trae Fitzgerald, the Chief Financial Officer of Viemed Healthcare, Inc. (the "**Company**"), hereby certify, that, to my knowledge:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.The Quarterly Report on Form 10-Q for the period ended June 30, 2025 (the "**Report**") of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;&nbsp;&nbsp;&nbsp;The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 6, 2025

---

| |
|:---|
| /s/ Trae Fitzgerald |
| Trae Fitzgerald<br>Chief Financial Officer |

---

<br>